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1 Introduction 
1.1 Hepatocellular carcinoma 
1.1.1 Epidemiology 
According to the World Health Organization’s (WHO) GLOBOCAN report on 
estimated cancer incidences, there were 14.1 million cases of new occurrences 
of malignant diseases with 8.2 million cancer-related deaths in 2012 [1]. 
Therefore, cancer is the leading cause of death in the world. The WHO’s World 
Cancer Report [2] states that hepatocellular carcinoma (HCC) has been the 
second most common cause of cancer mortality worldwide with a total of about 
0.8 million reported deaths in 2012 (see Figure 1.1). 
 
Figure 1.1: Cancer-related deaths 2012 
Estimated percentage distribution [%] and number of cancer-related deaths (total: 8,201,575) worldwide in 
2012 for both sexes and all ages. Generated at: http://globocan.iarc.fr/Pages/online.aspx, retrieved: 
06.03.2015, data based on WHO, Globocan, IARC, 2012 [1]  
Persistent HBV (Hepatitis B Virus) and HCV infections (Hepatitis C Virus) are 
predominant risk factors for the development of primary liver cancer, especially 
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in regions of the world with high incidences of infections (i.e. Africa, Eastern Asia). 
In industrial nations, liver cirrhosis based on ethanol abuse, intoxications (e.g. 
aflatoxin) and on grounds of a metabolic syndrome are relevant etiologic factors 
for the occurrence of hepatocellular carcinoma [3]. 
1.1.2 Current state-of-the-art treatment options for liver cancer 
Traditionally potentially curative treatment options for this heterogeneous 
malignant tumor are resection of small tumors, percutaneous ablation or liver 
transplantation, which all are subject to (i) a very early-stage disease at diagnosis 
and (ii) surgical inclusion criteria like whether or not the vascular system is 
infiltrated or residual functional capacity of remaining liver (most recently 
reviewed in [4]). Despite substantial efforts to improve median survival of patients 
with advanced stage HCC, prognosis of this type of cancer is still dismal (recently 
reviewed in [5]). In most cases, progression of the disease can be delayed only 
transiently and long-term disease suppression or even cure cannot be achieved 
by current pharmacological therapies. Thus, treatment with sorafenib (Nexavar®), 
the only approved first-line systemic therapy for patients with advanced stage 
HCC, results in only a modest prolongation of median survival of about three 
months [6]. Several late-stage (II/III) clinical trials employing drugs with distinct 
mechanisms of action (e.g. tyrosine kinase inhibitors, Epidermal Growth Factor 
Receptor (EGFR) blockers, Vascular Endothelial Growth Factor (VEGF)-
Receptor blocker etc.) yet failed to prove superiority compared to the current first-
line treatment option for advanced HCC. Accordingly, further improvements in the 
treatment of late-stage HCC are desperately needed. 
1.2 Oncolytic virotherapy as an innovative approach in cancer 
treatment 
Oncolytic viruses (OVs) represent a novel therapeutic approach (so-called 
virotherapy) in the treatment of various malignant neoplasia, employing their 
ability to selectively infect, replicate in and (onco-)lyse tumor cells, without 
affecting normal tissues. In this chapter, a brief reflection on the history of 
oncolytic viruses will be given, along with the introduction of general 
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virotherapeutic principles and a short summary of viruses being tested in the 
clinical setting on cancer patients. 
1.2.1 History of oncolytic viruses 
The idea of employing natural occurring pathogenic viruses as anti-cancer agents 
was initially based on several observations of tumor regression in patients with 
coincidental natural virus infections [7] or subsequent to vaccinations with live 
attenuated viruses [8, 9]. Early anecdotes of spontaneous disease remission 
following infection were made even before the “discovery” of viruses as 
contagious agents [10]. Contagion with wild-type measles virus was reported to 
be coincidental with regressions of leukemia [11, 12], Morbus Hodgkin [13, 14] 
and a well-documented case of Burkitt’s lymphoma [15]. Early clinical trials used 
primitive techniques for administration of naturally occurring viruses, as infectious 
body fluids or infected tissue samples were applied to tumor patients. 
Unsurprisingly, adverse events were serious and unpredictable [7] and therefore 
early enthusiasm for virotherapy abated until technical advantages allowed to 
engineer viruses with beneficial tissue tropism and restricted replication-
competence to malignant tissue. 
1.2.2 Principles of oncolytic virotherapy 
Oncolytic virotherapy is an emerging novel approach in treating malignant 
diseases using live attenuated, naturally occurring or genetically modified virus 
vectors with selective tropism for neoplastic cells. This oncotropism is a result of 
epigenetic and genetic alterations in the process of malignant transformation (e.g. 
[17]), as tumors acquire the potency to dampen innate and adaptive immune 
responses by hiding immunogenic tumor neo-antigens and escaping immune 
effector cells [18], which in turn creates an ideal niche for viral particles that are 
otherwise unable to infect healthy cells (see Figure 1.2).  
“The field of oncolytic virotherapy undoubtedly has made formidable progress 
since first ever replication-competent, genetically engineered viruses have 
entered preclinical & clinical testing in the 1990s [19]. The first clinical trials with 
such modified/attenuated virus pathogens used as oncolytic vectors primarily had 
to address numerous safety concerns. But ever since, oncolytic viruses have 
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proven to constitute generally well-tolerated novel biological anti-cancer drugs 
[20].  
However, when coming to the efficiency of the oncolytic paradigm, many 
limitations of those first-generation virotherapeutics regarding anti-tumor efficacy 
became obvious [21]. Accordingly, next generation oncolytics were designed (i) 
to enhance tumor specificity, (ii) to express efficiency-boosting transgenes, such 
as suicide genes or immunomodulatory cytokines, or (iii) to coat viruses as 
camouflage (to avoid rapid neutralization when getting in contact with the highly 
effective anti-viral host immune response) [22]. Latest evidence suggests that 
anti-tumor activity of oncolytic viruses is not solely dependent on pathogen-
mediated direct/specific infection and (onco-)lysis of malignant cells but is also 
capable of triggering an adaptive anti-tumor immune response. In this context, 
current evidence suggests that the mechanisms of action of virotherapeutics can 
be attributed at least partly (i) to a profound exposure of antigenic tumor epitopes 
being released in huge amounts throughout the oncolytic process, (ii) to a 
subsequent inflammatory tumor infiltration as well as (iii) to the induction of a T-
cell-mediated anti-tumor immune response (see original work [23-26] as well as 
data reviewed in [18]).” [27] 
 
Figure 1.2: Principles of oncolytic virotherapy using the example of oncolytic measles vaccines. 
Modified from Kirn D et al. [16] 
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1.2.3 Oncolytic virus families in clinical testing 
Several oncolytic viruses are currently under investigation in various clinical trials 
as biological treatment options for a wide array of tumor entities. The catalogue 
of ongoing or finalized clinical trials comprises a plethora of different viral vectors, 
e.g. Adenovirus (notably, in 2006, the ONYX-015 derivative Adenovirus H101 
was the first approved oncolytic vector for tumor therapy in China [28]), 
Coxsackievirus, Herpes Simplex Virus (HSV), Measles Vaccine Virus 
(Edmonston Strain), Newcastle Disease Virus, Parvovirus, Poliovirus (Sabin 
Strain), Reovirus (Dearing Strain), Seneca Valley Virus, Retrovirus, Vaccinia 
(strains Lister, Wyeth, Western Reserve) and Vesicular Stomatitis Virus (VSV), 
which are administered as single agents in monotherapeutic approaches or 
combined with chemo-/radiotherapy [29].  
In late 2015, a first virotherapeutic compound received simultaneously approval 
by both U.S. Food and Drug Administration (FDA, see 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm469571.
htm, retrieved 05.04.2016) as well as European Medicines Agency (EMA, see 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2
015/10/news_detail_002421.jsp&mid=WC0b01ac058004d5c1, retrieved 
05.04.2016), based on positive results of a Phase III clinical trial [30]: patients 
with late stage malignant melanoma (showing recurrence after initial surgical 
procedures) have now access to the first-in-market virotherapeutic agent 
IMLYGIC™ (AMGEN, Thousand Oaks, CA, USA), a genetically modified HSV-1 
virus (also known as Talimogene Laherparepvec, T-Vec). Most interestingly, 
approval by regulatory authorities of this leading virotherapeutic vector was 
received although as primary endpoint a durable response rate (complete or 
partial response) of “only” 16.3% was achieved in patients receiving T-Vec/ 
IMLYGIC™ (compared to 2.1 percent of patients in the control group (p <0.0001)) 
for at least six months. On the contrary, improvement in overall survival (OS) 
within the patient group of this phase III trial (n=292 patients receiving virus 
dosages) could not be observed and effects on visceral metastases were likewise 
(statistically) non-detectable (see also section 1.2.4). 
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These results strongly indicate that the establishment of oncolytic virotherapy as 
a new pillar of cancer treatment started with the approval of IMLYGIC™ (the 
pioneering work in this field was therefore particularly acknowledged by 
FDA/EMA), but nevertheless efficacy of this innovative treatment option needs to 
be significantly improved. This could be achieved by introducing novel, more 
powerful vector systems (i.e. modified oncolytic viruses) and furthermore, 
reasonable combination strategies have to be established.  
Table 1.1 presents a quick overview of current or completed clinical trials using 
viruses as monotherapeutic agents with their corresponding application scheme 
sorted by oncolytic vector platforms as well as by the respective identifiers 
provided by http://clinicaltrials.gov/ (NCT). 
Virus family Vector Route Application scheme References 
Adenovirus 
ColoAd1 
(enadenotucirev) 
Intratumoral/ 
Intravenous 
Arm 1:  Single shot 
NCT02053220; 
[31] 
Arm 2:  Triple-hit course (d1, d3, 
d5) 
Intravenous One triple-hit course (d1, d3, d5) NCT02028442 
ICOVIR-5 
Intravenous 
Weekly intravenous infusions of 
bone-marrow derived autologous 
Mesenchymal Stem Cells (MSCs) 
infected with ICOVIR-5 (=CELYVIR) 
NCT01844661 
Intravenous Single shot NCT01864759 
CG0070 
Intravesical 
Weekly intravesical 
administration           (6 courses) 
NCT01438112 
Intravesical 
Arm 1:  Weekly intravesical 
administration (6 courses) NCT00109655; 
[32] Arm 2:  Every 4 weeks (for up to 6 
courses) 
DNX-2401  
(Delta-24-RGD) 
Intratumoral Single shot NCT00805376 
Intraperitoneal Triple-hit course (d1, d3, d5) 
NCT00562003; 
[33] 
Coxsackievirus CAVATAK 
Intratumoral 
10 intratumoral injections over 18 
weeks (d1, d3, d5, d8, d22, d43, 
d64, d86, d106 + d127) 
NCT01227551; 
[34] 
Intratumoral 
Group 1:  Single shot 
NCT00832559 
Group 2:  Three injections (d1, d3, 
d5) 
Group 3:  Six injections (d1, d3, d5, 
d7, d9, d11) 
Intratumoral Two injections (d1, d3) NCT00438009 
Intratumoral Single shot NCT00235482 
Table 1.1: Selected clinical trials using oncolytic vector systems as monotherapeutic agents 
(Table published in [27]). d1, d2, d3: day 1, day 2, day 3; i.v.: intravenous; IP: intraperitoneal).  
Table continued on next page. 
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Virus family Vector Route Application scheme References 
Herpes 
simplex virus 
Talimogene 
Laherparepvec  
(T-Vec/IMLYGIC™) 
Intratumoral 
First injection on d1, second 
course 3 weeks from initial dose, 
all subsequent courses every 2 
weeks 
NCT02014441 
Intratumoral 
First injection on d1, second 
course 3 weeks from initial dose, 
all subsequent courses every 2 
weeks 
NCT00769704; 
[30] 
Intratumoral See above; up to 24 courses 
NCT00289016; 
[35] 
Intratumoral 
Three injections every 3 weeks 
(plus max. three additional 
courses) 
NCT00402025; 
[36] 
M032 
Intra-
/Peritumoral 
Single shot NCT02062827 
Seprehvir  
(HSV 1716) 
Intravenous/ 
intratumoral 
Part 1:  Single shot  
Part 2:  plus max. 3 additional 
courses 
NCT00931931; 
[37] 
Intrapleural 
Part A:  Single shot 
NCT01721018 
Part B:   
Group 1: 2 courses at weekly 
intervals  
Group 2: 4 courses at weekly 
intervals 
Intra-
/Peritumoral 
Single shot NCT02031965 
HF10  Intratumoral 
Stage 1:  Single shot 
NCT01017185; 
[38] Stage 2:  4 courses (dosing  
interval ≥ 2 weeks) 
rRp450 
into hepatic 
artery 
4 courses every 1-2 weeks NCT01071941 
Measles 
Vaccine virus 
(Edmonston 
strain) 
MeV-CEA 
Intratumoral/ 
into resection 
bed 
Arm 1:  Single shot 
NCT00390299 
Arm 2:  Two-hit-course (d1, d5) 
Intraperitoneal Every 4 weeks for up to 6 courses 
NCT00408590; 
[39] 
MeV-NIS 
Intrapleural Every 4 weeks for up to 6 courses NCT01503177 
Intraperitoneal Every 4 weeks for up to 6 courses 
NCT00408590; 
[40] 
Intraperitoneal 
Course 1:  Only MeV-NIS IP; 
NCT02068794 
Subsequent courses:  MeV-NIS 
infected mesenchymal stem cells 
IP (every 4 weeks for up to 6 
courses) 
Intratumoral Single shot NCT01846091 
Intravenous 
Arm 1:  Single shot 
NCT00450814; 
[41] 
Arm 2:  Single shot in combination 
with  Cyclophosphamide 
Parvovirus ParvOryx 
Intratumoral/ 
Intravenous 
Two courses (d1, d10) 
NCT01301430; 
[42] 
Polio-Virus  
(Sabin strain) 
PVS-RIPO Intratumoral Single shot 
NCT01491893; 
[43] 
Table 1.1: Continued 
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Virus family Vector Route Application scheme References 
Reovirus 
(Dearing 
strain) 
Reolysin 
Intratumoral Single shot 
NCT00528684; 
[44] 
Intravenous 
Up to 12 quintuple-hit courses 
(d1-5) every 4 weeks 
NCT00651157; 
[45] 
Intravenous 
Quintuple-hit courses (d1-5) every 
4 weeks 
NCT00503295; 
[46] 
Intravenous/ 
Intraperitoneal 
Administration i.v. as quintuple-
hit courses (d1-5) every 4 weeks + 
additional IP administration on 2 
consecutive days beginning with 
course 2 
NCT00602277 
Intravenous 
Up to 12 quintuple-hit courses 
(d1-5) every 4 weeks 
NCT01533194 
Intravenous 
Up to 12 quintuple-hit-courses 
(d1-5) every 4 weeks NCT01240538 
Senecca Valley 
virus  
NTX-010 
Intravenous Single shot 
NCT01017601; 
[47] 
Intravenous Single shot 
NCT00314925; 
[48] 
Vaccinia virus 
(Lister strain) 
GL-ONC1 
(GLV-1h68) 
Intraperitoneal Every 4 weeks (4 courses) 
NCT01443260; 
[49] 
Intrapleural Single shot NCT01766739 
Intravenous 
Arm 1:  Every 4 weeks (up to 6 
courses) 
NCT00794131; 
[50] 
Arm 2:  Every 4 weeks (3 triple-hit-
courses d1, d2, d3) 
Arm 3:  Every 4 weeks (3 
quintuple-hit-courses d1, d2, d3, 
d4, d5) 
Vaccinia virus 
(Western 
Reserve 
strain) 
vvDD-CDSR 
(JX-929) 
Intratumoral/ 
Intravenous 
Single shot 
NCT00574977; 
[51] 
Vaccinia virus 
(Wyeth strain) 
JX-594 
(pexastimogene 
devacirepvec,  
Pexa-Vec) 
Intratumoral 3 courses every 2 weeks 
NCT00554372; 
[52] 
Intratumoral Every 3 weeks (max. 8 courses) 
NCT00629759; 
[53] 
Intratumoral Weekly (up to 6 courses) 
NCT00429312; 
[25] 
Intravenous Single shot 
NCT00625456; 
[54]  
Intravenous Every 2 weeks (up to 4 courses) 
NCT01380600; 
[55] 
Intravenous 
Treatment on d1, d8, d22 and 
weeks 6, 12, 18 
NCT01387555; 
[56] 
Intravenous 
Weekly for 5 weeks (followed by 
up to 3 additional infusion boosts) 
NCT01394939 
Intravenous 
Weekly for 5 weeks, then every 3 
weeks 
NCT02017678 
Intravenous Every 2 weeks NCT01469611 
Intravenous 
Weekly for 5 weeks (treatment 
extension:  i.v. infusion every 3 
weeks in case of stable disease) 
NCT01636284 
Vesicular 
Stomatitis 
Virus  
VSV-IFN-beta Intratumoral Single shot NCT01628640 
Table 1.1: Continued 
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1.2.4  “Assessment of current virotherapeutic application schemes” [27] 
Acknowledging the outstanding importance to (i) enhance efficiency of direct 
oncolysis-mediated tumor cytoreduction and (ii) to maximize an anti-tumor 
immune response following virus infection, analysis of application schemes for 
virus administration in clinical trials is crucial to a successful oncolytic immuno-
therapy. “Prime examples for success achieved so far in virotherapy have to be 
discussed and correlated with the respective application regimes which might 
have fostered these (rare) success stories. This kind of analytic view quite 
stringently leads to the conclusion that not only one, but presumably two quite 
divergent application strategies could lead to success, i.e. “hit hard and early” 
and “killing softly”, reflecting also the two quite opposite paradigms of “single-
shot” and “prime-boost” regimens (see Figure 1.3). 
 
Figure 1.3: Prime-Boost / Single-Shot paradigms of virotherapeutic application schemes. 
(Figure modified from published version [27]) 
The prime-boost paradigm (Figure 1.3 (A), upper panel) encompasses a huge 
variation in the number of application courses (see also Table 1.1) of oncolytic 
1 Introduction 
10 
 
viruses either applied as single-hit (d1 only) or multiple-hit courses (d1, d2, …, 
dx). Here, priming of an anti-tumor immune response (depicted in the left part of 
the panel) is the result of initial tumor-cell infection and colonization [], 
replication [] and subsequent oncolysis []. After eventual decrease of this 
primary anti-tumor immune response, the second and every following course of 
repetitive virus application is used under the premise (i) to further debulk 
remaining tumors using once again mechanisms of direct virus-mediated 
oncolysis [++] and (ii) boosting the anti-tumor immune response (depicted 
in the right part of the panel) by releasing concealed tumor antigens within the 
meaning of an anti-tumor vaccination [21]. Preferential route of administration 
here is an intratumoral injection, as a rapid neutralization of viruses by a 
simultaneously triggered anti-viral immune response (depicted by a red arrow-
type rectangle) can be avoided. In addition, multiple-hit courses in the prime-
boost setting are limited by an anti-viral immune response as well, since the 
adaptive immune response is fully qualified often at the latest seven days after 
the first injection and thus further virus applications are considered as ineffective. 
Therefore, intervals between courses have to find a balance between attacking 
the tumor as soon as possible and simultaneously avoiding premature 
neutralization of the virotherapeutic vectors. The single-shot paradigm (see 
Figure 1.3 (A), lower panel) is in accordance with the initial understanding of the 
“oncolytic virotherapy paradigm” [29], as it is believed that a single systemic 
administration of oncolytic viruses leads to a systemic spread with subsequent 
selective primary infection [] of the primary site of the tumor as well as of 
disseminated metastases. Self-amplification/ replication [] of virotherapeutic 
vectors is followed by direct tumor-cell (onco-)lysis [] and recognition of infected 
tumor cells by the innate host immune system with subsequent clearance of 
residual tumor masses through a tumor antigen triggered adaptive host-immune 
response []. Basic prerequisite for a successful utilization of the single-shot 
paradigm is to maximize the initial dosage of applied infectious particles as dose-
dependent tumor colonization [] and subsequent oncolysis of disseminated 
tumors is only achievable if a viremic threshold is passed [57]. Below this 
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threshold, systemically administered virus particles are immediately neutralized 
by preexisting antibodies or serum factors, such as complement [58]. 
The prime-boost paradigm in rare cases of success (Figure 1.3 (B)) addresses 
rare patient specific defects in the anti-viral immune response being so far 
undetected and clinically silent. Thereby, a prolonged replication/ oncolysis (for 
several weeks) generating quasi prime-boost situation is probably generated with 
the help of nature. 
The “single-shot” paradigm (Figure 1.3 (A), lower panel) is best represented by 
the recent report on two measles-seronegative patients with relapsing drug-
refractory myeloma being both treated by a single-shot intravenous infusion with 
a very high dosage of the measles vaccine virotherapeutic MeV-NIS leading in 
one patient to a durable complete remission at all disease sites [41]. Key factors 
postulated to have contributed to this successful outcome were mentioned as 
follows: (i) low pretreatment serum titers of anti-measles antibodies; (ii) usage of 
a very high virus dosage being sufficient to overcome a postulated dose-threshold 
required for successful tumor colonization; (iii) detection of measles virus 
transcripts (but not of live virus particles) in circulating cells even at 6 weeks after 
virus infusion, by which time there had been a substantial boost to the anti-
measles antibody titer, suggesting the possibility of a continuing oncolytic activity 
even at that late time (Figure 1.3 (B)). 
The “prime-boost” paradigm (Figure 1.3 (A), upper panel) is best represented by 
the recent OPTiM phase III virotherapy study in which the HSV-1 based, GM-
CSF encoding virotherapeutic vector talimogene laherparepvec (T-Vec, 
IMLYGIC™) was applied intralesional/intratumoral in unresected stage IIIB/C and 
IV melanomas [59].  
Following an initial dose (functioning as a priming of the anti-tumor immune 
response; Figure 1.3 (A), upper panel, on the left), dosing of T-Vec/IMLYGIC™ 
was repeated every 2 weeks for up to 24 times defining a therapy intense 
“multiple-shot/long-term application” scenario, being in maximum contrast to any 
of the single-shot scenarios. Based on this application regime, T-Vec/IMLYGIC™ 
proved it could shrink tumors, keep them from regrowing and improve median 
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survival. However, T-Vec/IMLYGIC™ hit its primary endpoint of durable response 
but missed its second goal of boosting overall survival (p value of 0.051; see: 
[30]). 
As premises for successful oncolytic virotherapy are multifactorial and multi-
dimensional, several key factors contribute to an enhanced treatment efficacy 
which can be demonstrated using the example of T-Vec/IMLYGIC™ skin-cancer 
treatment: melanoma as a tumor entity seems to be highly vulnerable to 
oncolysis, as virotherapeutic treatment effects were also found following JX-594 
vaccinia injections [24]. Both T-Vec/IMLYGIC™ and JX-594 were administered 
in conformance with the prime-boost paradigm, supporting to further cherish this 
application scheme in melanoma treatment. Both, T-Vec/IMLYGIC™ and JX-594 
encode for human GM-CSF, an immunomodulating cytokine that is evaluated for 
the treatment of skin cancer as a monotherapeutic agent itself [60]. Therefore, 
this particular biology of vectors T-Vec/IMLYGIC™ and JX-594 seem to represent 
a qualified approach to this particular cancer biology. 
Putatively, as mentioned above, such “multiple-shot/long-term application” 
scenarios only can be successful if the respective virotherapeutics are applied 
intratumoral. Otherwise, the anti-virotherapeutic immune response (depicted as 
a red arrow-type rectangle in Figure 1.3 (A), upper panel), which often is induced 
as early as seven days after the very first virotherapeutic treatment, would 
completely block with great efficiency any subsequent colonization of the 
respective tumor sites, although this would be required for a repetitive boosting 
of the anti-tumor immune response (Figure 1.3 (A), upper panel, on the right). 
As to date no consent on either route of administration or preferential application 
scheme is established in the field and valuable data from clinical trials addressing 
those issues is still rare, it is not surprising that efficacy of clinical trials employing 
oncolytic viruses as monotherapeutics often fall short of expectations. Thus, to 
address those limitations of viral monotherapy (for details see also section 1.4), 
cunning combinational strategies are imploringly awaited for broad usage in 
clinical trials. 
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1.3 Oncolytic measles vaccine viruses 
1.3.1 Virus biology 
Measles virus (MeV) belongs to the group of negative-sense, single-stranded 
RNA viruses (-ssRNA), the family of Paramyxoviridae, and genus is classified as 
Morbillivirus (International Committee on Taxonomy of Viruses, ICTV, 2014). The 
highly contagious measles disease (clinical symptoms are fever, maculopapular 
exanthema, respiratory symptoms, conjunctivitis [61]) caused by MeV is an 
important cause of morbidity and mortality for children especially in developing 
countries, with an estimated global measles mortality of 139.300 in 2010 [62]. 
Six structural proteins are encoded by the negative-sense ssRNA (Figure 1.4): 
fusion protein F, hemagglutinin H, large protein L, phosphoprotein P, matrix 
protein M and the nucleocapsid protein N. 
 
Figure 1.4: Schematic morphology of measles virus:  
Measles virus is a negative sense single-stranded RNA virus encoding for six structural proteins (© Guy 
Ungerechts, NCT Heidelberg) 
The hemagglutinin and the fusion protein are integrated as transmembrane 
glycoproteins into the phospholipid bilayer of the envelope, which is descendent 
from the host cell membrane. Hemagglutinin is responsible for MeV receptor 
binding and therefore initiation of infection, as the following receptors can be 
recognized by H protein: SLAM (signaling lymphocyte activation molecule)/ 
CD150 is a glycoprotein expressed on B and T cells [63], dendritic cells (DC), 
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Langerhans cells (LC) and macrophages [64] and therefore determining the 
lymphotropism of MeV. In 2011, an epithelial cell adherens junction protein, 
Nectin-4, was identified as a MeV receptor [65, 66] as well.  
Another MeV receptor, human membrane cofactor protein (CD46) is ubiquitously 
expressed on all human nucleated cells and involved in complement activation 
and regulation of immune response [67-70], but utilization as MeV receptor was 
found to be limited to vaccine strains of measles and not the wild-type viruses 
[71]. These findings are of clinical importance, as Edmonston strain measles 
vaccine viruses (MeV-Edm) are used as oncolytic viruses for cancer treatment 
(see section 1.3.3). Anderson and colleagues[72] found CD46 expression levels 
to be crucial for successful occurrence of typical MeV-mediated cytopathic effect 
- portrayed by syncytia forming (i.e. cell-cell-fusion) - as MeV entry and also 
substantial oncolysis correlated positively with CD46 receptor densities on tumor 
cells. Additionally, CD46 expression levels in cancer cells are frequently found to 
be elevated as a tumor cell-mechanism to prevent complement-mediated 
oncolysis [73, 74] and, by implication, selectively targeting oncolytic measles 
vaccine viruses to this particular subset of neoplastic tissue. 
After binding to target cells utilizing the H protein, MeV entrance into host cells is 
mediated by the fusion protein F and virus propagation in the cytoplasm of the 
host cell is dependent on a negative sense ribonucleo-protein complex (RNP), 
comprised of the RNA strand, the N structural protein, as well as the RNA 
dependent RNA polymerase (composed of the viral L and P protein) [75]. 
Besides, two non-structural proteins are encoded on the measles genome: V 
protein, which participates in the inhibition of several pro-inflammatory signaling 
cascades [75] and C protein, with various functions including suppression of viral 
transcription and replication [76] as well as controverse interactions in 
circumvention of host interferon-induction (discussed in [75]). 
1.3.2 Suicide transgene expressing MeV-SCD 
As mentioned above (see section 1.2.2), first-generation oncolytic vectors often 
lacked sufficient anti-tumor activity, but genetic engineering makes it possible to 
enhance efficacy by inserting transgenes into viral nucleic acid encoding e.g. for 
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transmembrane channels (that can later be used to deliver cytotoxic 
radioisotopes into tumor cells), immunostimulating factors (such as GM-CSF, see 
above) or prodrug converting enzymes. 
In this thesis, we used a recombinant Edmonston strain derived measles vaccine 
virus encoding for a fusion protein (Super-Cytosine Deaminase, Super-CD or 
SCD) [78] of cytosine deaminase (CD; yeast origin) and uracil phosphoribosyl-
transferase (UPRT; also yeast origin) [79] to boost catalytic enzyme activity of 5-
FC (5-fluorocytosine)  5-FU (5-fluorouracil) conversion and subsequent steps 
in this prodrug toxification (see Figure 1.5). 
 
Figure 1.5: Mechanism of action of MeV-SCD prodrug convertase Super-Cytosine Deaminase (SCD):  
Prodrug 5-fluorocytosine (5-FC) is converted into chemotherapeutic 5-fluorouracil (5-FU) by cytosine 
deaminase part of SCD. 5-FU is further metabolized by orotate phospho-ribosyltransferase or alternatively 
by uracil phosphoribosyltransferase (UPRT) domain of SCD into 5-fluorouridine monophosphate (5-FUMP). 
5-FUMP can further be metabolized to the corresponding triphosphate 5-fluorouridine triphosphate, which is 
falsely integrated into RNA as a substrate of RNA polymerase. Reduction of 5-FUMP results in 5-
fluorodesoxyuridine monophosphate (5-FdUMP), which is an inhibitor of thymidylate synthase and can also 
be triphosphorylated to 5-desoxyfluorouridine triphosphate (5-dFUTP), which leads to DNA damage by 
incorporation. SCD activity is responsible for a reduction of 5-FU clearance by dihydropyrimidine 
dehydrogenase (DPD, localized in the liver) into dihydrofluorouracil (DHFU) with subsequent renal excretion 
after further metabolization. Figure modified from Longley et al.[77].  
Enzymatic conversion of 5-FC - a pyrimidine analogue that is clinically applied as 
an antimycotic drug [80] - into the well-established chemotherapeutic 5-FU is 
catalyzed by cytosine deaminase, which is part of the bifunctional enzyme-
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complex SCD. UPRT participates in the conversion of 5-FU into 5-fluorouridine 
monophosphate (5-FUMP) [81]. 
Cytotoxic effects of 5-FU are mediated by (i) covalent inhibition of tumor cell 
thymidylate synthase leading to a lack of newly synthesized thymidine [82], (ii) 
direct damage to RNA as well as DNA through insertion of 5-FU as an 
antimetabolite (reviewed in [83]). 
The introduction of the bifunctional enzyme complex SCD into tumor cells that 
are selectively infected with MeV-SCD allows the systemic administration of the 
prodrug 5-FC, as conversion into cytostatic 5-FU is restricted to SCD-expressing 
tumor cells. Therefore, manifold higher concentration of the chemotherapeutic 5-
FU can be accomplished at the site of the tumor with a reduction of systemic 
toxicities to a minimum and as 5-FU is highly diffusible, primarily unharmed 
cancer cells after virus infection are also affected by 5-FU, which is known as a 
so-called “bystander effect” [84]. 
1.3.3 Measles vaccine viruses (MeV)-based oncolytic monotherapy in 
selected clinical trials 
Measles vaccine virus (MeV) has been safely applied to millions of patients during 
vaccination programs as live-attenuated commercial vaccine since 1963 [85] and 
has ever since shown excellent safety profiles, which also applies for the clinical 
setting when used as anti-cancer agents. As outlined above (see section 1.2.4), 
analysis of application schemes for virus administration can help to identify 
limitations to MeV-based oncolytic mono-virotherapy (see also section 1.4). Here, 
“a comprehensive assessment of current application schemes could help to 
identify basic application approaches and assign these to successful regimens” 
[27] also for measles vaccine-based oncolytic virotherapy.  
Thus, in this section, current state-of-the-art application schemes for MeV clinical 
trials are condensed and displayed in two easy-to-read figures: 
“To date, two Edmonston strain-derived measles vaccine viruses (MeV-Edm) are 
intensively explored clinically, namely MeV-CEA and MeV-NIS. MeV-CEA 
encodes for carcinoembryonic antigen which can be employed as a marker gene 
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for viral gene expression in vivo [86]. MeV-NIS encodes for the human thyroidal 
sodium iodide symporter and can be used for both non-invasive imaging for viral 
gene expression e.g. by SPECT/CT and for radiovirotherapy e.g. with ionizing 
gamma-radiation-emitter 131I radioiodine [87]. 
Repetitive application schemes for MeV: 
First results of a MeV-CEA dose-escalating clinical trial on refractory ovarian 
cancer (NCT00408590) were published in 2010 [39]. Patients were treated with 
MeV-CEA through an intraperitoneal catheter every 4 weeks for up to 6 courses 
(application scheme depicted in Figure 1.6 (A)). Treatment was well tolerated, as 
no dose-limiting toxicities occurred. Anti-tumor activity led to stable disease in 
14/21 patients with a median duration of 92.5 days. CEA marker-gene detection 
was reported in peritoneal fluid and serum favorably in patients receiving high 
dosages of the study virus. Encouraged by these results, MeV-NIS was also 
applied to women diagnosed with drug-resistant ovarian cancer in a subsequent 
part of the same phase I/II trial (NCT00408590). Again, MeV-NIS was 
administered into the peritoneal cavity every 4 weeks for up to 6 courses (see 
Figure 1.7 (A)) and results regarding safety and efficacy correlated well with the 
previous MeV-CEA trial but additional information was gained by radio imaging 
of viral gene expression [40]. 
Pointing out a high level of protocol adherence, another phase I trial on malignant 
pleural mesothelioma (NCT01503177) also applied MeV-NIS with 6 courses 
every 4 weeks into the pleural cavity (see Figure 1.7 (B)). 
Notably, another innovative application scheme is included in the protocol of 
another MeV-NIS clinical trial on therapy-resistant ovarian cancer 
(NCT02068794): intraperitoneal application on the first course with MeV-NIS is 
followed by subsequent courses every 4 weeks for up to 6 courses with MeV-NIS 
infected mesenchymal stem cells (MSC). These cell-based virus delivery 
systems are administered intraperitoneally as well (see Figure 1.7 (C)). The use 
of virus-loaded cell carriers to evade premature sequestration of virotherapeutics 
by the host immune response (e.g. by preexisting anti-measles antibodies) after 
an initial uncoated loco-regional (i.e. intraperitoneal) measles infection has 
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already shown very promising results in a xenograft mouse model. Tumor-
specific infiltration of parenchyma with subsequent virus delivery by measles 
virus-infected mesenchymal stem cells was found to prolong overall survival 
when compared to “naked” infectious virus particles in mice. Therefore, a strong 
preclinical rationale had been built for exploring this innovative application design 
in the clinical setting [88]. 
MeV single-shot application schemes: 
Russell and colleagues [41] from the Mayo Clinic have recently presented a case 
report (NCT00450814) describing a durable complete remission of a patient with 
therapy-refractory multiple myeloma after a single shot of intravenous MeV-NIS 
(see Figure 1.7 (D)). MeV-NIS expression allowed the investigators to monitor 
infection of disseminated tumor sites with subsequent vanishing of all detectable 
tumor masses. Another application of a single shot of MeV-NIS in the treatment 
of head and neck cancer is part of a phase I trial (NCT01846091) but here 
administered by intratumoral injection (see Figure 1.7 (E)). A trial with MeV-CEA 
on brain and central nervous system tumors (NCT00390299) is using an altered 
application scheme. A single-shot application into the resection cavity after brain 
surgery is compared to a double-hit course with one application pre-surgery (via 
catheter) and another post-surgical intervention into the resection cavity 
(application scheme also depicted in see Figure 1.6 (B)). 
As outlined above, insights gained from the MeV-NIS trial on multiple myeloma 
serve as a prime example to substantiate the single-shot “hit hard and early” 
paradigm. Here, Russell and colleagues provided a proof-of-principle that a 
single shot of systemically administered MeV at the maximum achievable dosage 
could lead to a complete clinical response even at advanced stages of disease. 
Key factors for a successful implementation of the single-shot paradigm were 
proposed to be the high dosage of infectious particles used for patient treatment 
(= “hit hard”) and no detectable amount of preexisting anti-virus serum antibodies 
(= “hit early”; i.e., prior to induction of a virus-specific immune response).” [27] 
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Figure 1.6: Selected application schemes of MeV-CEA: 
(B) results published by Galanis et al. [39]; (figure modified from published version [27]) 
 
Figure 1.7: Selected application schemes of MeV-NIS: 
(A) Results published by Galanis et al. [40], (D) results published by Russell et al. [41]; (figure modified from 
published version [27]) 
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1.4 Limitations to oncolytic virotherapy 
Oncolytic virotherapy still struggles with various limitations, e.g. in case of 
measles virus, its premature neutralization by preexisting antibodies in the 
vaccinated population. This limits its clinical efficacy, as only few virotherapeutic 
particles are able to reach the respective tumor sites. Beyond that, phenomena 
of primary tumor cell resistances against MeV-based virotherapeutics also seem 
to constitute an important issue [89]. Recently, a screening of 54 cell lines derived 
from solid tumors revealed a high variation of susceptibility to measles virus-
mediated oncolysis, revealing primary resistance phenomena to virotherapy in 
about 50% of all tested human tumor cell lines [90]. A further screening on a 
human sarcoma cell line panel revealed that differences of acquired defects in 
innate immunity signaling pathways are crucial for the efficiency of MeV-mediated 
oncolysis, as most resistant tumor cell lines were shown to exhibit at least partly 
intact IFN signaling pathways [79]. To further address those issues, combination 
strategies for oncolytic viruses are desperately needed, as it is more likely to 
exploit the full potential of virotherapy by affiliating the viral vectors with suitable 
combination partners. 
In case of MeV-Edm-based virotherapy, there have been several approaches to 
challenge these limitations: employing the expression of the NIS transgene, pre-
clinical studies of a radiovirotherapeutic approach showed enhanced anti-tumor 
effects when MeV-NIS was co-administered with ionizing gamma-radiation-
emitter 131I radioiodine [91] and MeV-CEA with conventional radiation even 
demonstrated synergistic benefits of this combinational approach [92]. 
The group of epigenetically operating histone deacetylase inhibitors (HDACi) 
distinguished itself to be of special interest for combination with OVs since they 
are believed to have a great potential to unmask cancer antigens as they destroy 
malignant cells and promote an inﬂammatory response [93] but are likewise able 
to prevent initial innate immunity signaling in infected tumor cells. 
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1.5 Innate immunity signaling following oncolytic virus 
infection 
“In response to viral pathogens, mammalian cells have developed an arsenal of 
innate immunity factors to prevent viral infections, with a central role assigned to 
the interferon (IFN) system [94]. Virus derived pathogen-associated molecular 
patterns (PAMPs) are detected by e.g. cytoplasmic viral nucleic acid sensors 
such as RIG-I (retinoic acid-inducible gene 1) and MDA5 (melanoma-
differentiation-associated protein 5) [95] or membrane associated Toll-like 
receptors (TLRs) [96], with subsequent activation of downstream NF-κB signaling 
[97] or IRF-3/IRF-7 binding to the IFN promoter site [98], resulting in transcription 
and secretion of type I interferons. Autocrine and paracrine produced IFN binds 
to the membrane associated IFN-receptor with consecutive activation of the 
downstream JAK/STAT signaling pathway [99]. As a result, transcription of IFN 
stimulated genes (ISG) is induced, such as IFN-induced proteins with 
tetratricopeptide repeats (IFIT family), establishing an antiviral state within the 
infected cell as well as in non-infected bystanding cells [100]. Recently, it was 
shown that measles virus (MeV) vaccine strains such as the Edmonston strain of 
MeV, but not wild-type MeV, induce production of IFN-β, e.g. via IRF-3 activation 
[101, 102]. Since MeV-based virotherapeutics are generated on backbones of 
MeV vaccine strains [29, 79], MeV-induced production of IFN-β could have strong 
implications on rates of primary infection, replication and spread of MeV in tumor 
tissues, thereby constituting a severe limitation to MeV-based oncolytic 
virotherapy approaches.” [103] 
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1.6 Inhibitors of histone deacetylases (HDACi) 
1.6.1 Principles of HDACi-based cancer therapy 
 The family of human histone deacetylases aggregates 18 protein complexes 
subdivided into four classes (class I, IIa/b, III, IV) in analogy to yeast HDACs with 
distinct enzymatic activity and localization within the cell [105]. Histone 
deacetylases are enzymes (together with e.g. histone acetyl transferases (HAT), 
DNA methyltransferases, etc.), involved in epigenetic regulation of gene 
expression, catalyzing posttranslational modification of histones (see Figure 1.8). 
 
Figure 1.8: Principles of histone deacetylase inhibition.  
Histone acetyl transferases (HAT) catalyze the transfer of an acetyl group (from acetyl-CoA) on lysine amino 
acids of histone proteins. Removing of these acetyl groups is catalyzed by histone deacetylase (HDAC) 
enzymes, leading to the formation of a tight DNA-chromatin complex and subsequent transcriptional 
suppression. Inhibition of HDACs results in less compact coiling of negatively charged phosphate backbone 
of DNA around histone proteins. This relaxed chromatin allows increased transcriptional activity of former 
silenced genes. Figure modified from Kazantsev et al.[104]. 
In particular, HDAC catalyze removing of acyl groups on acetylated lysine 
residues of histones resulting in an electrophysiological condensation of histone 
proteins with DNA phosphate backbones and subsequent transcriptional 
suppression [106]. 
Among classical mechanisms of carcinogenesis involving malignant alterations 
in DNA sequences, epigenetic modifications - including acetylation and 
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methylation of histones - seem to be of particular importance during malignant 
transformation [107, 108]. 
The restoration of the non-transformed (i.e. the non-malignant/healthy) condition 
of these structurally intact (but disorganized through epigenetic regulation) genes 
has evolved as a potential target for HDACi cancer therapy, either by prohibiting 
an improper recruitment of HDACs to DNA promoter sites, by epigenetic 
modification of non-histone proteins, or by induction of pro-apoptotic genes that 
were otherwise aberrantly silenced in malignant cells [109, 110]. 
As a result, inhibition of histone deacetylases in cancers was found to result in 
cell cycle arrest or implementation of an intrinsic as well as extrinsic apoptotic 
program together with antiangiogenic and immunomodulatory effects [105, 110]. 
In 2006, the first histone deacetylase inhibiting compound vorinostat (SAHA) 
received FDA approval for treatment of cutaneous T-cell lymphoma (CTCL) and 
in 2009, the HDACi Romidepsin was approved for peripheral T-cell lymphoma 
[111, 112]. In contrast, epigenetic compounds have yet to demonstrate their 
potential to be efficient in the treatment of solid tumors as most HDACi clinical 
trials showed limitations in anti-tumor activity with at least to some extent 
concomitant toxicities [113]. As employment of epigenetic compounds as 
monotherapeutics is subject to particular controversy (e.g.: is pan-HDAC 
inhibition of therapeutic benefit compared to single class or single enzyme 
inhibiting compounds? [114]), these issues have to be further addressed before 
implementation into clinical routine. Combination of HDACi with other established 
cancer treatment regimen showed encouraging additive or even synergistic 
effects (e.g. [115, 116]). Proof of principle has been demonstrated for 
combination with other epigenetic compounds, such as DNA methyl transferases 
[117-119], microtubule interfering compounds, such as paclitaxel [120], 
proteasome inhibitors (such as bortezomib, marizomib, and carfilzomib) [121-
123], conventional chemotherapeutic drugs (such as platinum based agents, 5-
fluorouracil, gemcitabine, epirubicin) [124] and importantly conventional radio-
therapy [125].  
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Therefore, inhibitors of histone deacetylases have emerged as ideal combination 
partners to overcome resistances, enhance therapeutic efficiency and on top of 
this minimize toxicities, as combinational approaches allow to reduce therapeutic 
dosages applied to cancer patients [110]. 
The special interest of histone deacetylase inhibition in combination with oncolytic 
virotherapy as an innovative treatment option for various malignancies is covered 
in section 1.7. 
1.6.2 Resminostat, a novel histone deacetylase inhibitor 
Involvement of epigenetic alterations are found for the origination and 
development of HCCs as well (reviewed in [126]). Preclinical and clinical studies 
have demonstrated inhibition of histone deacetylases by HDACi to be an efficient 
treatment option for this specific tumor entity [127-129].  
“Resminostat constitutes an oral histone deacetylase inhibitor currently 
undergoing clinical evaluation in several phase I/II clinical trials in patients with 
advanced stage HCC (NCT00943449)” [103], patients exhibiting refractory 
Hodgkin’s lymphoma (NCT01037478), patients with advanced colorectal cancers 
(NCT01277406) and a small study on advanced solid tumors in a Japanese 
cohort [130]. 
The SHELTER (NCT00943449) study evaluated resminostat in combination with 
sorafenib compared to resminostat-monotherapy as second-line treatment option 
in patients with HCC progression under first-line sorafenib treatment. Here, a 
median overall survival of 8.1 months (resminostat + sorafenib) compared to 4.2 
months in the resminostat monotherapy arm was achieved. This median overall 
survival (OS) in the combination arm means a benefit of nearly 3 months 
additional survival compared to an expected median OS of 5.2 months after tumor 
progression under sorafenib first-line therapy [131, 132]. Thus, resminostat 
showed – while being generally well tolerated – potential to re-sensitize therapy-
refractory liver cancer to sorafenib treatment.  
The SAPHIRE (NCT01037478) trial on relapsed/refractory Hodgkin’s lymphoma 
(HL) showed clinical efficacy of resminostat monotherapy for this malignancy as 
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19/34 patients (55.6%) obtained PET/CT accessed response or stabilization of 
disease [133]. 
In the SHORE (NCT01277406) trial on advanced colorectal cancer (CRC) 
resminostat was tested in combination with standard FOLFIRI therapy regimen 
and was overall found to be well tolerated and safe, as no dose limiting toxicities 
were observed [134]. 
Mechanistically, resminostat was found to inhibit class I and IIb HDACs 
(especially isoenzymes 1, 3, and 6) and therefore, by changing the acetylation 
status of both histones and other cellular proteins, altering the gene expression 
and transcriptional profile within tumor cells. “In vitro resminostat was shown to 
induce apoptosis in concentrations above 2.5 μM, whereas lower concentrations 
resulted in a proliferation stop and cell cycle arrest [135].” [103]  
Recently, zinc finger protein 64 (zfp64), a DNA binding transcription factor, was 
identified as a surrogate parameter for resminostat treatment, its expression 
being downregulated as early as 5 hours after treatment with resminostat [136]. 
Clinical evaluation hereby revealed that biomarker zfp64 could potentially predict 
resminostat responses in cancer patients as high zfp64 expression levels before 
treatment intervention correlated with achievement of a longer overall survival 
(OS) in Hodgkin’s lymphoma and hepatocellular carcinoma patients [131].  
It is of special interest that resminostat proved its immunomodulating potency 
(see Figure 1.9) in vitro by enhancing the expression of several tumor associated 
antigens (TAA), by enhancing the expression of MHC I molecules and – in 
addition – by enhancing the expression of NKG2D ligands on tumor cell surfaces 
(including hepatoma cell line HepG2) and therefore boosting the recognition and 
subsequent NK cell-mediated killing of cancer cells. On top of this, resminostat 
treatment showed potential to re-establish antitumor immunosurveillance by 
reducing expression of both Indoleamine 2,3-dioxigenase 1 (IDO1) and 
Arginase1 [137] which are essential for repression of T-cell activation leading to 
peripheral tumor tolerance (reviewed in [138, 139]). 
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“This profile proposes resminostat as an interesting partner for novel epi-
virotherapeutic concepts in the combinatorial treatment of patients exhibiting 
advanced stages of HCC” [103]  
 
Figure 1.9: Immunomodulating effects of resminostat  
Inhibition of different histone deacetylases by resminostat alters acetylation status of histones as well as 
other proteins resulting in altered transcriptional activity within tumor cells. Upregulation of NKG2D ligand 
expression on HepG2 cell surface leads to an enhanced recognition and subsequent elimination of tumor 
cells by natural killer cells (NK cells). On the other hand, resminostat treatment results in an enhanced 
expression of tumor-associated antigens (TAA), boosting a T-cell-mediated anti-tumor adaptive immune 
response. Downregulation of both Indoleamine 2,3-dioxigenase 1 (IDO1) and Arginase1 (ARG1) blocks 
unspecific tumor cell evasion of the patient’s immune system. For further details, see text. 
Figure modified from Hamm et al.[137] 
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1.7 Epi-virotherapeutic combination therapies  
As described above, successful oncolytic virotherapy (OV) depends to a great 
extent on tumor biology specifics. Therefore, combining OVs with immuno-
modulating compounds (such as HDACi) or radio-/chemotherapy promises to 
improve the prospect of successful virotherapeutic treatments [140, 141]. 
Successful combinations of HDACi and OVs have been reviewed by Nguyen et 
al.[142], revealing distinct mechanisms of action, depending (i) on the specifics of 
viral vectors in use as well as (ii) on the individual HDACi used.  
Recently, re-sensitization to vesicular stomatitis virus (VSV) induced oncolysis by 
HDAC inhibitors like entinostat (MS-275) and vorinostat (SAHA) has been 
demonstrated to result in a significant improvement of viral replication [143] in 
preclinical studies. Interestingly, entinostat combined with a virotherapeutic 
prime-boost using vectors of VSV and adenovirus origin, both expressing human 
dopachrome tautomerase (hDCT), were found to suppress primary immune 
responses, but to enhance secondary immune responses, resulting in a 
prolonged survival in a murine melanoma model [144]. In another experimental 
system, vaccinia virus replication and spread were found to be boosted by 
combination with the HDAC inhibitor trichostatin A (TSA) [145, 146]. A similar 
pattern was found for the combination of herpes simplex virus (HSV) and the 
HDAC inhibitor valproic acid (VPA) [147] revealing that VPA treatment impaired 
recruitment of immune cells as well as innate immunity signaling [89]. Replication 
of HSV was found to be intensified when employing a whole panel of different 
HDACi [148] and additional anti-angiogenic effects were identified for the 
combination of TSA plus HSV [149]. Another virotherapeutic vector, parvovirus 
H-1PV, led to additional functional insights on potential combinational 
mechanisms: addition of VPA was found to increase acetylation and thereby 
cytotoxicity of the NS1 protein of H-1PV [150]. HDAC inhibition in combination 
with adenovirus results in the upregulation of CAR, a membrane receptor for 
coxsackie and adenovirus subgroups [151]. However, opposite outcomes such 
as VPA-mediated inhibition of both adenovirus replication and spread have also 
been reported [152], indicating that every individual combination of HDAC 
inhibitor and oncolytic virus has to be investigated in detail.” [103] 
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1.8 Objective 
Despite recent accomplishments in establishing oncolytic viruses as a new 
therapeutic option for cancer patients with advanced-stage disease, oncolytic 
virotherapy was found to face various limitations in clinical trials, which 
encompass not only poor delivery of virotherapeutics to tumor sites, but also 
primary and secondary resistances against those virotherapeutics resulting in 
rapid and uncontrolled tumor progression.  
To address those limitations, epigenetic compounds, especially histone 
deacetylase inhibitors (HDACi), seem to be qualified for putative combination (i.e. 
epi-virotherapeutic) strategies in the field of oncolytic virotherapy. 
Based on encouraging results in combining oncolytic viruses with histone 
deacetylase inhibitors, the aim of this dissertation was to establish a preclinical 
therapy regimen for the epi-virotherapeutic approach in the treatment of hepato-
cellular carcinoma (HCC), using the prototypic suicide gene-armed measles 
vaccine-based virotherapeutic MeV-SCD and the oral HDACi resminostat (Res) 
for in vitro studies on a panel of three well-established hepatoma cell lines 
(HepG2, Hep3B & PLC/PRF/5). 
First, cytotoxic effects of both agents, resminostat & MeV-SCD, had to be tested 
on the hepatoma cell lines to determine single agent concentrations (for 
resminostat) and multiplicities of infection (MOIs, for MeV-SCD) to achieve a 
threshold of ≈75% of remnant tumor cell mass, ensuring still sufficient amounts 
of viable tumor cells available for combinational testing scenarios. 
As a next step, diverging application schemes had to be tested, varying the time 
schedule for both treatment modalities aiming to find out, whether pre- or post-
treatment with the epigenetic compound is of positive influence for the therapeutic 
outcome. For the most efficient approach it had to be tested if combination of 
MeV + Res is accompanied by enhanced toxicity for non-malignant liver cells. In 
addition, anti-tumor effects of a triple therapy, superinducing prodrug 5-FC 
conversion by SCD expressing, MeV-SCD-infected tumor cells, had to be 
determined to exploit the full potential of the prodrug conversion enzyme 
encoding measles virus. 
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To further characterize mechanisms of action in the epi-virotherapy-based 
oncocytotoxicity, cell cycle profiles were set out to evaluate differences in co-
treated cells compared to the corresponding single-agent treatments. 
Based on the results gained in the cytotoxicity assays, influences of resminostat 
HDAC inhibition on virus kinetics were investigated by working out viral growth 
curves and subsequent comparison between measles infection alone and in 
combination with resminostat. In a next step, alterations of measles primary 
infection rates under resminostat treatment needed to be determined as well as 
accompanying possible alterations in MeV entry-receptor (CD46) expression 
levels underlying an amended viral growth behavior. 
To further reinforce the arguments for the epi-virotherapeutic approach in 
advanced HCC, another aim of this thesis was to demonstrate immuno-
modulatory properties of resminostat relating to an enhanced efficacy of measles-
based virotherapy. This was set out to further simulate the in vivo situation, as an 
intact innate immunity signaling is crucial to oncolytic virotherapy. 
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2 Materials and Methods 
2.1 Safety 
The laboratory at Otfried-Müller-Str. 27, 72076 Tübingen, Germany, is 
constructed according to the “Act on the Prevention and Control of Infectious 
Diseases in Man” (Infektionsschutzgesetz, IfSG), of July 20, 2000, which is in 
conformity with the “directive 2000/54/EC” of the European Parliament and of the 
Council of September 18, 2000 “on the protection of workers from risks related to 
exposure to biological agents at work” for laboratories with Biosafety Level 2. 
Therefore, it was necessary that all experiments including work with potentially 
contagious or hazardous biological and non-biological agents were performed 
under a HERAsafe laminar flow laboratory hood (Heraeus; Hanau, Germany). 
Surfaces and materials were disinfected using 70% isopropanol (SAV Liquid 
Production; Flintsbach a. Inn, Germany) or Descosept (Dr. Schuhmacher GmbH; 
Melsungen, Germany) and irradiated with ultraviolet light. Both solid as well as 
liquid waste were autoclaved at 2 bar pressure and 121 °C for 20 minutes 
(Autoclave 3850 EL, Systec; Linden, Germany). 
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2.2 Cell biology methods 
2.2.1 Cell lines 
Name of the 
cell line 
Origin Source  
(Catalogue No) 
Morphology 
HepG2 Human hepatocyte carcinoma, 
15 year-old-male 
DSMZ  
(Catalogue No  
ACC 180) 
 
Hep3B Human hepatocyte carcinoma, 
8 year-old-male 
DSMZ  
(Catalogue No  
ACC 93) 
 
PLC/PRF/5 Human hepatoma, 
24-year-old male 
ECACC  
(Catalogue No  
85061113) 
 
VERO-B4 Monkey: African green monkey 
(Chlorocebus aethiops 
(Cercopithecus aethiops)) 
DSMZ  
(Catalogue No  
ACC 33) 
 
Table 2.1: Commercial cell lines used for the studies in this thesis:  
Data available online for ECACC (= European Collection of Cell Cultures) https://www.phe-
culturecollections.org.uk/ (retrieved: 23.08.2014) and DSMZ (= Leibniz-Institut DSMZ-Deutsche Sammlung 
von Mikroorganismen und Zellkulturen GmbH): http://www.dsmz.de/catalogues.html (retrieved 23.08.2014). 
Microscopic picture of VERO-B4 cells provided by Dr. Susanne Berchtold, UKT. 
2.2.2 General cell culture 
The cell lines listed in Table 2.1 were cultured in tissue culture flasks with filter 
caps (either 75 cm² or 150 cm², Greiner Bio One; Frickenhausen, Germany) and 
stored in an incubator at 37 °C in a humidified atmosphere enriched with 5% CO2. 
Hep3B and PLC/PRF/5 cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM, Sigma Aldrich; Munich, Germany) plus 10% Fetal Bovine 
Serum (FBS, biowest; Nuaillé, France). HepG2 cells were cultured using a 
minimum glucose DMEM (Sigma Aldrich) plus 10% FBS and additional L-
glutamine [10 ml/l]. Vero cells were cultured with DMEM plus 10% FBS. 
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“Stimulation with human Interferon-β (IFN-β; Pepro-Tech, Rocky Hill, NJ, USA) 
was achieved by adding 1,000 U/ml IFN-β to the culture medium.” [103] 
Cells in culture flasks were microscopically examined on a daily basis with a 
CK40 contrast light microscope (Olympus, Shinjuku, Tokyo, Japan). Once 
confluence in the cell layer was reached, cells were washed once with sterile 
phosphate buffered saline (PBS, Sigma Aldrich) and subsequently detached with 
Trypsin/EDTA solution (Biochrom, Berlin, Germany or Sigma Aldrich). After an 
incubation of 2-5 minutes at 37 °C the cells were brought into solution with the 
corresponding FBS-supplemented medium and either split and discarded or 
seeded in cell culture multiwell plates (6 well-plates, Corning, Tewksbury, MA, 
USA; 24 well-plates, TPP; Trasadingen, Switzerland; 96 well-plates, TPP & 
Corning). 
2.2.3 Cryoconservation of cultured cells 
All cell lines could be long-term stored in liquid nitrogen (LN2) at -196 °C or a 
freezer at -145 °C in a cryoconservation tube (1ml, Corning). Therefore, a cell 
suspension (prepared as described above) in a 50 ml conical-bottom tube 
(Falcon/BD Bioscience/Becton Dickinson, Franklin Lakes, NJ, USA) was 
centrifuged at 1300 rotations per minute (rpm) for 5 minutes, supernatant fluid 
was discarded and the cell pellet was resuspended in a cryoconservation medium 
(containing 90% DMEM-medium supplemented with 20% FBS and 10% 
Dimethylsulfoxid [DMSO, Appli Chem; Darmstadt, Germany]) and filled into the 
cryo tubes. 
2.2.4 Thawing of cell lines 
When a high number of passages was reached, which limited the “doubling 
potential” of our cultivated cells in vitro in accordance with the so called “Hayflick 
limit” [153] it was necessary to reculture the frozen cells. Therefore, frozen cells 
were thawed at 37 °C, suspended in 8 ml of warm DMEM supplemented with the 
appropriate amount of FBS and transferred into a 15-ml conical tube (BD 
Bioscience) and centrifuged with 1200 rpm at room temperature. The supernatant 
was discarded and the cell pellet was resuspended in 10 ml of fresh medium and 
transferred in a 75 cm2 tissue culture flask. 
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2.2.5 Cell counting using a Neubauer haemocytometer 
Determination of a diluted number of cells was accomplished using an improved 
Neubauer haemocytometer (see Figure 2.1) as described by Bastidas [154] 
(Celeromics; Grenoble, France): after getting the cells in suspension, the 
counting chamber was prepared by engaging the moistened covering glass with 
the central area of the Neubauer chamber. Then a 10μl sample of a cell 
suspension diluted with Trypan Blue (Biochrom) - which allows the differentiation 
between vital cells and dead ones - was pipetted close to the edge of the covering 
glass. After the sample had been soaked in by capillary action between covering 
glass and counting chamber, the chamber was examined under a CK40 light 
microscope (Olympus). The chamber’s counting grid is represented in Figure 2.2 
and is divided into small and large squares. The vital cells, which are not stained 
by Trypan Blue – since an intact cell membrane results in color retention of the 
dye – remain colorless in light microscopy. The four large squares were counted. 
As the distance between the covering glass and the bottom of the chamber is 0.1 
mm, a 0.1 mm x 0.1 mm large square contains a volume of 0.1 µl. 
 
Figure 2.1: Representative Neubauer haemocytometer used for cell counting. 
Hence, the formula of concentration calculation is: 
	 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Equation 1: Determination of cell count using a Neubauer counting chamber 
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Figure 2.2: Improved Neubauer chamber grid detail:  
Modified after manufacturer’s user’s guide www.celeromics.com/en/resources/docs/Articles/Cell-counting-
Neubauer-chamber.php (retrieved on 23.08.2014). Usage as described in the text. Red circle marks a large 
square. 
2.2.6 Infection with MeV-SCD/MeV-GFP and/or treatment with 
resminostat 
24 h before any treatment, a defined number of cells was seeded into cell culture 
multiwell plates. Cells were washed once with sterile PBS (37 °C) and infected 
with different multiplicities of infection of viral vectors diluted in reduced serum 
medium Opti-MEM (gibco, Grand Island, NY, USA). Three hours post infection 
(hpi), the supernatant was removed and replaced with growth medium or medium 
containing resminostat, which was generously provided by 4SC AG, Planegg-
Martinsried. Infection with measles vaccine virus MeV-SCD/MeV-GFP or 
treatment with the Histone-Deacetylase-Inhibitor (HDACi) resminostat was 
performed at variable orders and time-sequences, seeking for the most effective 
application setting. Further details will be described in section 3.2. 
  2 Materials and Methods 
35 
 
2.3 Virological methods 
2.3.1 Titration of measles vaccine virus 
“Construction of recombinant measles vectors MeV-GFP (measles vector 
encoding for green-fluorescent protein as a marker gene integrated into the viral 
genome) and MeV-SCD (encoding for suicide gene Super-cytosine deaminase, 
SCD [78]) has been described elsewhere [79].” [103] 
Production and propagation of the measles virus vectors were performed in our 
group, and therefore, it was necessary to determine the concentration of virus in 
different frozen stocks of virus solutions. Viral titers were defined using theTCID50 
(tissue culture infective dose 50) endpoint titration according to Spearman [155] 
and Kärber [156] and results were converted into plaque-forming units/ml 
(pfu/ml). 
24 h before infection with the virus containing sample, VERO cells were plated in 
a 96-well plate (Corning, 1 x 104 cells per well), diluted in 200 μl DMEM plus 5% 
FBS. The day of infection, a dilution row was prepared on a single row of twelve 
wells on a 96-well plate: first, the twelve wells were filled with 270 μl DMEM plus 
5% FBS per well. 30 µl of the original virus sample were pipetted into the first well 
and thoroughly mixed six times (resulting in a 1:10 dilution). The pipette tip was 
discharged and with a new tip, 30 µl of the 1:10 diluted viral sample were pipetted 
into the following well. This procedure was performed on all twelve wells, resulting 
in a dilution range from 10-1 to 10-12. Subsequently, the virus dilutions were 
transferred to the VERO cell plate, each dilution factor with a volume of 30 μl into 
all eight wells of a column (see Figure 2.3).  
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After incubation at 37 °C for 96 hpi, the VERO plate was examined under the light 
microscope and viral plaques, caused by cytopathic syncytia formation due to 
measles infection, were evaluated. Using this technique, all wells showing signs 
of viral infection were considered as “positive”. Immunofluorescence staining 
(only necessary for MeV-SCD) was executed for the last serial dilution with all 
“positive” wells, plus the following three dilution steps. Prior to staining, the entire 
plate was washed with 100 µl PBS per well (self-prepared: NaCl 137 mM (8 g) + 
KCl 2.7 mM (0.2 g) + Na2HPO4 10 mM (1.44 g) + KH2PO4 1.8 mM (0.24 g) + H2Odd 
filled up to 1 l) and then fixated with 50 μl of 4% paraformaldehyde (Otto Fischar 
GmbH) for 10 minutes and subsequently washed two times with PBS. The plates 
could then be stored at 4 °C for a few days. 
After blocking the unspecific protein-binding sides with 100 µl/well 1% FBS in 
TBS-T (TBS-Tween (0.02%): 5 ml Tween-20 + 500 ml 10 x TBS + H2Odd filled up 
to 5 l) and simultaneously permeabilizing the cell membrane of the fixed cells with 
Tween-20, which is included in the TBS-T buffer for intracellular antibody binding, 
Figure 2.3: Scheme of MeV titration on VERO cells:  
VERO cells seeded 24 hpi in a 96 well plate were infected with MeV-SCD with indicated dilution factors. As 
an example MeV-positive wells are colored in red, the first four columns were considered “all positive”. Staining 
with anti-NP-antibodies was executed in the area of the plate between the dotted lines. 
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the blocking solution was replaced after 30 minutes with 50 μl of the primary 
antibody “MeV N-Protein NP clone 120 Mouse IgG2” (ECACC), diluted 1:1000 in 
TBS-T. After another 30 minutes and three washing steps with TBS-T (100 µl per 
well), the secondary antibody “Alexa Fluor® 546 Goat Anti Mouse IgG (H+L), 
A11003” (Invitrogen, Carlsbad, CA, USA), diluted 1:1000 in TBS-T, was applied 
and incubated a last time for 30 minutes in the dark. After the final washing steps 
(three times with TBS-T) and addition of 100 μl PBS/well, the plate was analyzed 
via fluorescence microscopy using a fluorescence microscope IX50 (Olympus), 
which is able to visualize the fluorescence dye of the “Alexa Fluor 546®” 
secondary-antibody (excitation: 557 nm, emission: 572 nm). Wells were 
considered as “positive” when more than one fluorescent particle was present in 
one well (single fluorescent signals were considered as non-replication-
competent viral particles, which were excluded for determination of the viral titer). 
The calculation of the amount of infectious particles in the undiluted sample was 
calculated with the following formula: 
  ⁄  =  ∗ 10 !".#$%.#& 
Equation 2: Calculation of viral titers using the TCID50 method with included conversion into pfu/ml 
units. 
With:   a = 0.7 which is the conversion factor of the original TCID50-method to the 
less abstract unit plaque forming units (pfu) 
and  y = sum of the fractions of positive wells per dilution factor, e.g. for       
Figure 2.3 8/8 positive for the first 4 dilution factors (plus 8/8 for the 
undiluted) plus 5/8 for dilution factor 10-5 and 3/8 for dilution factor 10-6 
2.3.2 Viral growth curves 
To compare the kinetics of viral growth in our hepatoma cell lines after infection 
with MeV-SCD alone or in combination with resminostat, virus titration of samples 
taken at five different time points over a period of 96 h was performed. 
Therefore, HepG2, Hep3B and PLC/PRF/5 cells were plated in a 24-well plate 24 
h before infection. The hepatoma cells were infected with adjusted MOIs (see 
Table 2.2), as preliminary experiments revealed varying susceptibility of different 
cell lines to viral oncolysis. Three hours post infection, after washing the plate 
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three times with PBS, the inoculum was substituted with DMEM or DMEM-
containing resminostat (1 µM). The first set of samples was collected immediately 
by pooling the supernatants of four wells of the same treatment into a 2-ml 
reaction tube (Eppendorf, Hamburg, Germany), then adding 0.5 ml OptiMEM per 
well and scraping the attached cells into the medium with a pipette tip. The cell 
suspensions of the two different treatment modalities were likewise filled into 2 
ml reaction tubes. The samples were frozen at -80 °C until further usage. This 
procedure was repeated every 24 h until 96 hpi. 
Cell line Number of cells per well MOI (MeV-SCD) c(resminostat): [3 hpi] 
HepG2 4 x 104/well 0.15 1 µM 
Hep3B 3 x 104/well 0.01 1 µM 
PLC/PRF/5 2 x 104/well 0.075 1 µM 
Table 2.2: Plating/treatment conditions for sample collection in the viral growth curves experiments. 
Adjusted number of cells per well and adjusted MOIs and were empirically determined by viability assays 
(as described in section 2.5). MOI: multiplicity of infection; c: concentration; hpi: hours post infection 
After all samples had been collected, the day before titration, Vero cells were 
plated as described in section 2.3.1. The following day, the samples were thawed 
in a water bath (Köttermann, Uetze/Hänigsen, Germany) at 37 °C for only a few 
minutes, thoroughly vortexed and centrifuged at 3.000 rpm for 2 minutes. Dilution 
of the samples was performed according to a similar protocol as described above, 
but differed because serial dilution was carried out in a column of eight wells on 
a 96-well plate and more importantly, the first well was filled with 300 μl of 
undiluted centrifuged supernatant, owing to the experience that the viral titer in 
the samples taken from the non-optimal growth system (in this case the 
hepatoma cell lines) was lower than those of the pure virus stocks. The serial 
dilution of eight factors was then transferred using a multichannel pipette 
(Eppendorf), applying a volume of 50 µl per well to the VERO cells. This process 
was repeated for three further wells. 
The read-out of the infected VERO cell plates was carried out exactly as 
described above in section 2.3.1. 
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2.3.3 Fluorescence microscopy on MeV-GFP infected cells 
To visualize viral spread in the hepatoma cells, cells were seeded in 6-well culture 
plates the day before infection. Inoculation with MeV-GFP was performed with 
standardized multiplicities of infection [133] of 0.1 (pfu/cell) and 1 (pfu/cell) for all 
cell lines. Substitution of the virus containing OptiMEM with DMEM plus 
resminostat was implemented three hours post infection. Every 24 h for up to four 
days, comprehensive fluorescence microscopy was realized, using an IX50 
(Olympus) microscope with a permanently connected F-view camera system 
(Soft Imaging System GmbH, Münster, Germany). Analysis 3.1 software (Soft 
Imaging System GmbH) was used for post-processing phase contrast pictures 
(taken with 50 ms exposure time) as well as for fluorescence pictures (taken with 
3000 ms exposure time). Both images were finally overlaid with the photoshop 
software GIMP 2 (free download available at http://www.gimp.org/).  
Cell line Number of cells per well MOI (GFP) c(resminostat) [3 hpi] 
HepG2 4 x 105/well 0.1 & 1 1 µM 
Hep3B 2.5 x 105/well 0.1 & 1 1 µM 
PLC/PRF/5 1.5 x 105/well 0.1 & 1 1 µM 
Table 2.3: Conditions for fluorescence microscopy of MeV-GFP experiments 
MOI: multiplicity of infection; c: concentration; hpi: hours post infection 
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2.4 Flow Cytometry 
2.4.1 Analysis of altered primary infection rates by fluorescence-
activated cell sorting (FACS) using MeV-GFP 
“Human hepatoma cells (1.5 - 4 x 105/well) were cultured in 6-well plates and 
then infected with a measles vaccine virus encoding a GFP marker gene (MeV-
GFP) at MOI 1 and treated with resminostat at 1 μM. At 24 hpi, hepatoma cells 
were washed once with 2 ml PBS/well and detached with 0.5 ml Accutase (PAA 
Laboratories, Cölbe, Germany). Subsequently, Accutase was inactivated with 2 
ml FACS-buffer (PBS plus 10% FBS). Tumor cells were washed with PBS. After 
 
Figure 2.4: Schematic construction of a flow cytometer as used for analysing MeV-GFP infection 
rates, CD46-expression on hepatoma cells and analysis of cell cycle phases:  
The sample cells pass a laser beam, which is scattered by the passing cell. The FSC-Diode detects the 
scattered light that correlates with the size of the cell. Emitted fluorescence signals from stimulated  
fluorescent molecules (i.e. GFP or PE) are filtered by dichroic mirrors and detected by additional diodes. 
GFP = green-fluorescent-protein, PE = phycoerythrin; CD46= Cluster of differentiation, FSC= foreward-
scatter, FL1/FL2= name of channel, SSC= side-scatter. For further details see text. Figure based on 
http://www.semrock.com/Data/Sites/1/semrockimages/drawings/flow-cytometry_500.jpg (accessed: 
07.09.2014) and http://www.tiho-hannover.de/uploads/pics/Flowzytografik_10.jpg (accessed 07.09.2014). 
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centrifugation (302 x g, 5 min), the cell pellet was resuspended in FACS buffer. 
Cells were fixed by adding paraformaldehyde (Fischar) to a final concentration of 
1.3%. Differences in rates of primary infection were analyzed on the FACSCalibur 
cytometer (Becton Dickinson, Franklin Lakes, NJ) and digitally processed with 
the CellQuest software (Becton Dickinson).” [103] 
2.4.2 Quantitative analysis of CD46 receptor expression using flow 
cytometry 
To further investigate the molecular mechanisms that underlie the combined 
treatment of the marker-gene expressing measles vaccine virus MeV-GFP and 
the HDACi, alterations of CD46-receptor expression in the hepatoma panel were 
investigated by fluorescence-activated cell sorting (FACS). To quantify the 
expression of the cellular receptor for measles virus binding (CD46) on cancer 
cells by flow cytometry, CD46 was labelled with an anti-CD46-antibody 
(eBioscience) that is conjugated with the fluorescent dye phycoerythrin (PE).  
Within the flow cytometer, cells in solution pass, one by one, through a laser 
beam. A Forward Scatter (FSC-) diode detects the diffraction of emitted light and 
calculates the diameter of the passing cell, whereas different emitted fluorescent 
signals (which occur after stimulation with the laser beam) are detected by 
additional fluorescent channel diodes. Filters ahead of these diodes allow only 
one particular wavelength of light to pass (e.g. virus encoded eGFP emission 
wavelength: 509 nm), enabling the flow cytometer to detect different fluorescent 
signals within/on the cell currently rushing past (see Figure 2.4). In our case, the 
flow cytometer allowed us to calculate mean fluorescence indices for anti-CD46-
surface-protein-stained cells under the influence of MeV-GFP and/or resminostat 
(co-)treatment. Isotype control staining is necessary to calculate the amount of 
non-specific background signals of the conjugated antibody. 
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Cell line Number of cells per well MOI (GFP) c(resminostat) 
HepG2 4 x 105/well 1 1 µM 
Hep3B 4 x 105/well 1 1 µM 
PLC/PRF/5 1.5 x 105/well 1 1 µM 
Table 2.4: Cell culture conditions in CD46-expression experiments. 
MOI: multiplicity of infection; c: concentration 
The preparation of samples was performed as follows and is a modified protocol 
of Kolev and Kemper [157]: cells were seeded in 6-well plates and treated under 
the conditions listed in Table 2.4. Two wells of the same condition were pooled 
to ensure a suitable number of cells. At 24 hpi, cells were washed once with 2 ml 
of PBS per well and removed from the culture vessel by adding 1 ml of Accutase 
for 3-5 minutes, which was inactivated by 2 ml of FACS buffer per well. Transfer 
into a 15 ml conical tube was followed by 5 min of centrifugation at 1200 rpm. 
After counting the cells in a disposable Neubauer counting chamber (C-Chip, 
Biochrom), 5 x 105 cells for the CD46 staining and the same count for an isotype 
control sample were transferred into 5-ml round-bottom tubes, washed with 3 ml 
of PBS, resuspended in 50 μl FACS buffer and 10 μl of Gamunex (=human IgG 
immunoglobulin; Grifols, Barcelona, Spain), which blocks unspecific Fc receptor 
binding sides, were added to the solution. 5 min of incubation on ice was 
terminated by adding 2.5 μl of PE-conjugated anti-human CD46-antibody 
(eBioscience) or 2.5 μl of PE-conjugated mouse IgG1κ as the isotype control 
(eBioscience) with a subsequent incubation for 30 minutes at 4 °C in the dark. 
After a washing step with 3 ml of PBS, centrifuging as described before and 
resuspending the cell pellet in 200-500 μl FACS buffer, flow cytometry could be 
performed using the FACSCalibur flow cytometer. CellQuest software was used 
during measurement and for post-processing digital data. 
2.4.3 “Analysis of cell cycle profiles by flow cytometry 
For this assay, human hepatoma cells (2 - 4 x 104/well) were again cultured in 
24-well plates and infected with MeV-SCD the next day at indicated MOIs in Opti-
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MEM. Three hours post infection, medium was changed to DMEM or DMEM 
containing 1 μM resminostat. After an incubation period of 96 h, cells were stained 
using the Nicoletti staining protocol [158]: both cell culture medium as well as 
PBS, which was used to wash the plates, were collected together with the cells, 
being detached by using trypsin. Cells were centrifuged at 300 x g. The cell pellet 
was resuspended in a hypotonic propidium iodide buffer (1 mg/ml sodium citrate; 
0.003 ml/l Triton X-100; 0.02 mg/ml Ribonuclease A; 0.1 mg/ml propidium iodide, 
filled up with double distilled water) and cells were incubated for 30 min in the 
dark. As the buffer solubilizes plasma membranes and RNAse digests 
intracellular RNA, propidium iodide as an intercalating nucleic acid binding 
fluorescent dye interacts exclusively with intracellular DNA in a proportional 
manner. As the intracellular DNA content is dependent on the stages of the cell 
cycle, cellular DNA content indicates in which phase of the cell cycle the 
trespassing cell currently is (e.g. hypoploid signals are detected in apoptotic 
cells). Fluorescence signals were detected on a FACSCalibur flow cytometer 
(Becton Dickinson) and data analysis was performed using FLOWJO flow 
cytometric analysis program (FLOWJO LLC; Ashland, OR, USA).“ [103] 
2.5 Cell Mass and Viability Assays 
2.5.1 Sulforhodamine B (SRB) cytotoxicity assay 
As a routine screening method for cytotoxicity of the compounds under 
investigation, we used the Sulforhodamine B (SRB) cytotoxicity assay, which was 
first described by Skehan and colleagues [159]. The SRB dye binds to basic 
amino acid residues of protein chains under acid conditions and can be brought 
into solution under basic conditions. The amount of the released dye follows a 
linear correlation to the number of remaining cells and can be measured in a 
photometer [160].  
As the SRB cytotoxicity assay is an endpoint measurement, cells were cultured 
and treated as described before (see section 2.2.6) in 24-well plates and after the 
appropriate incubation time, plates were washed once with 0.5 ml ice-cold PBS 
and fixed with 250 µl 10% trichloroacetic acid (TCA) per well. The plates were 
then stored at 4 °C for 30 minutes and thereafter, the TCA was removed and the 
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plates were washed four times with tap water. Subsequently, the plates were 
dried at 40 °C for at least 24 h. The protocol then demanded the addition of 250 
µl SRB staining solution (Sigma Aldrich, 0.4% w/v in 1% acetic acid) per well, 
which was removed after 10 minutes of gently shaking by washing the plate four 
times with 1% acetic acid to remove unbound staining solution. Following at least 
6 hours of drying, the cell-bound dye was dissolved with 0.5 ml-2 ml of 10 mM 
TRIS pH 10.5 (Sigma Aldrich) per well. After a 10 minutes incubation period with 
careful shaking, the samples were transferred into a transparent flat bottom 96-
well plate as duplicates with a volume of 80 μl each. For determination of optical 
density (OD), the microtiter plate reader Tecan Genios Plus (Tecan, Maennedorf, 
Switzerland) was used with an excitation filter of 550 nm and the data was 
processed by the XFluor 4 (Tecan) software. 
2.5.2 CellTiter-Blue® Cell Viability Assay 
To confirm our cytotoxicity data gained from the SRB assay, we chose the more 
functional CellTiter-Blue® Cell Viability Assay, as this assay indicates the 
metabolic capacity of the treated cells, which is considered to be a direct marker 
of cell viability. The CellTiter-Blue® assay is based on the measurement of the 
potential of cells to reduce the active compound resazurin (7-Hydroxy-3H-
phenoxazin-3-one 10-oxide) which is dark blue and non-fluorescent. Reduction 
of the dye to the pink and fluorescent resofurin by the cellular redox system is 
proportional to the number of viable cells and can be measured by a fluorometer 
or photospectrometer [161]. 
Treatment conditions were the same as for the SRB assay (see section 2.5.1) 
and the assay was used as an endpoint measurement after the scheduled 
incubation time. As treatment was carried out in 24-well plates, the 
manufacturer’s protocol had to be slightly adapted. “To ensure equal amounts of 
culture medium per well, the supernatants of all wells of the same condition were 
pooled in a 2-ml reaction tube and 200 μl were readded per well. The admixture 
of 40 µl CellTiter-Blue® reagent (Promega, Madison, WI) per well started the 
incubation time that had to be empirically determined and took 1 h for HepG2 
cells. Read-out was performed on the microtiter plate reader Tecan Genios Plus 
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(Tecan) with an excitation filter of 584 nm and run under the XFluor software.” 
[103] 
2.6 Molecular Biology Methods 
2.6.1 Immunoblotting 
2.6.1.1 Preparation of cell lysates 
“Human hepatoma cells were seeded in 6-well plates (1.5 - 4 x 105/well) and the 
next day stimulated with 1,000 U/ml IFN-β and/or treated with 5 μM resminostat. 
Another 24 hours later, cells were washed with PBS and transferred into lysis 
buffer (50 mM Tris, 150 mM NaCl, 1% IGEPAL CA-630 [Sigma-Aldrich]). A total 
of three freeze-thaw cycles was followed by centrifugation to remove cell debris” 
[103], supernatants were transferred into new 1.5 ml reaction tubes and stored at 
-20 °C until further usage (see section 2.6.1.2 and section 2.6.1.3). 
2.6.1.2 Bradford protein dye assay for measuring protein concentrations 
To determine the concentration of total protein in the cell lysates, a quantification 
assay first described by M. Bradford [162] was performed, which is based on the 
shift in absorption maximum of the Coomassie Brilliant Blue G-250 dye after 
binding to the protein in solution. Binding to arginine-rich and aromatic sides of 
the proteins [163] causes a color change from red/brown to blue. This change in 
color is concentration-dependent and can be extrapolated by reference to a 
standard curve. 
We used the BIO-RAD protein assay kit (Bio-Rad Laboratories GmbH, Hercules, 
CA, USA) to determine the amount of protein in our lysates.  
A calibration curve was established by a serial dilution of a bovine serum albumin 
(BSA) protein standard (Roth; stock solution: 10 mg/ml) ranging from 0.5, 0.25, 
0.1, 0.05 to 0 mg BSA/ml in H2Odd. 10 μl of the BSA serial dilution as well as 10 
μl of the 1:20 diluted samples were pipetted as duplicates in a 96-well flat bottom 
microtiter plate and 200 µl of the 1:5 diluted (in H2Odd) Bradford dye (Bio-Rad 
Laboratories GmbH) was supplemented. 
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Absorbance at 595 nm was measured in a 96-well microplate ELISA reader 
Genios Plus (Tecan) run by the magellan software and calculation of protein 
concentration based on the Lambert-Beer’s law by referring to the standard 
curve. 
2.6.1.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
20 ml resolving gel (8% acrylamide) 
H2Odd 9.3 ml 
30% acrylamide mix (Carl Roth) 5.3 ml 
1.5 M Tris (pH 8.8) 5.0 ml 
10% SDS (= sodium dodecyl sulfate) 0.2 ml 
10% APS (= ammonium persulfate) 0.2 ml 
TEMED (= tetramethylethylendiamine) 0.016 ml 
Table 2.5: Ingredients of the resolving gel used for SDS-PAGE:  
To start the polymerization process of the acrylamide APS and TEMED were added last. 
8 ml stacking gel (5% acrylamide) 
H2Odd 5.5 ml 
30% acrylamide mix (Carl Roth) 1.3 ml 
1 M Tris (pH 6.8) 1.0 ml 
10% SDS (= sodium dodecyl sulfate) 0.08 ml 
10% APS (= ammonium persulfate) 0.08 ml 
TEMED (= tetramethylethylendiamine) 0.008 ml 
Table 2.6: Ingredients of the 5% stacking gel used for SDS-PAGE:  
To start the polymerization process of the acrylamide APS and TEMED were added last. For detailed 
production information see text. 
The emended method used in this thesis for separating proteins according to their 
molecular weight was first described by U. Laemmli in 1970 [164]. This assay 
uses a denaturation step as well as β-mercaptoethanol, which is an ingredient of 
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the loading buffer, to detach tertiary structure elements in proteins resulting in a 
linearized amino acid chain. Sodium dodecyl sulfate (SDS) is an anionic 
detergent that binds protein in a size-dependent way, negatively charging the 
proteins proportional to their mass [165]. 
To produce two 1.5-mm polyacrylamide gels consisting of a stacking gel (5% 
acrylamide) fraction and a resolving gel (8% acrylamide) fraction, 20 ml of the 
resolving gel solution (Table 2.5) were filled between two glass plates, covered 
with 70% isopropanol and left until polymerization was completed (about 30 
minutes). After discarding the isopropanol and washing the gel surface with 
H2Odd, the stacking gel solution (Table 2.6) was filled on top of the resolving gel 
and a ten-fingered comb was inserted. After 15 minutes of polymerization, 
removing the comb left pockets in the stacking gel, which could be used for 
protein insertion. 
Subsequently, the gels were assembled in an electrophoresis chamber which 
was filled with a 1:5 H2Odd diluted 5x running buffer (15.1 g/l Trizma Base, 72 g/l 
Glycine, 5 g/l SDS, filled up to one liter with H2Odd). 
To 40-50 µg of a protein sample a fifth of the sample volume 6x loading buffer 
(37.5 ml TRIS 1 M pH= 6.8; 30 ml Glycerol, 12.3 g SDS, 60 mg bromphenole blue 
filled up to 100 ml with H2Odd plus additional 60 µl β-mercaptoethanol) was added 
and the mixture was boiled up to 95 °C for 5 minutes and centrifuged afterwards. 
The first pocket of the gel was filled with 5 µl of a prestained PageRuler Plus 
protein ladder (Thermo Scientific, Waltham, MA, USA), whereas the protein 
samples were pipetted in the remaining pockets. Vertical electrophoresis was 
executed at a constant voltage of 70 V until all samples reached the resolving gel 
and then carried out with a constant amperage of 40 mA for one to two hours. 
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2.6.1.4 Western Blotting 
 
Figure 2.5: Correct arrangement of accessories and supplies in a Western Blot "sandwich": 
All parts were clamped in the blotting system, keeping the gel in close contact with the membrane, ensuring 
that no air bubbles were trapped between the different components. 
The separated proteins were electrophoretically transferred from the gel onto a 
polyvinylidene difluoride (=PVDF) membrane, where the proteins bind due to 
hydrophobic or polar interferences [165]. 
For electrophoretic blotting a blotting system of BioRad was used which made 
the correct arrangement of accessories and supplies (see Figure 2.5) necessary. 
Before stacking, the PVDF membrane was activated in methanol, washed once 
with H2Odd and then soaked together with the other materials in transfer buffer 
(48 mM TRIS; 39 mM glycin; 20% methanol, filled up with H2Odd). 
The “sandwich” was installed into the blotting chamber, which was then filled with 
blotting buffer and cooled with an ice pack. Electrophoretic transfer was 
performed for 1 h at 300 mA.  
After the transfer, the membrane was fixed in methanol and then stained with 
Ponceau S solution (0.1% Ponceau S [Sigma Aldrich] in 5% acetic acid,) to 
ensure successful protein transfer onto the membrane. At this point, marker 
bands were traced and the membrane was cut into two pieces at a predefined 
marker band of the rainbow colored protein ladder (e.g. at the red marker band 
which represented a molecular weight of 70 kDa). The membrane was rinsed with 
H2Odd to remove Ponceau S dye and then incubated for 1 h in 5% milk powder 
(Roth, blotting grade & low fat) dissolved in TRIS-buffered saline including 0.02% 
Tween 20 (= TBS-T: 150 mM NaCl, 13 mM TRIS, 0.02% Tween 20) to block 
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unspecific binding sites. Incubation over night at 4 °C with primary antibodies (for 
details see Table 2.7) was followed by three washing steps for 15 minutes with 
TBS-T and addition of the secondary antibody for 1 h at room temperature while 
shaking. To remove unbound antibodies, the membranes were washed once 
again for 3 x 10 minutes with TBS-T. Visualization of protein bands was 
performed with an enhanced chemiluminescence (= ECL) Western Blotting 
Detection Reagents kit (GE Healthcare Ltd, Buckinghamshire, UK) that uses the 
horseradish peroxidase (HRP)-coupled secondary antibody to blacken a high 
performance chemiluminescence film Amersham Hyperfilm™ ECL (GE 
Healthcare Ltd). A Fuji developer (Fuji Photo Film Ltd) was used to develop the 
films.  
Table 2.7: List of antibodies used for Western Blotting:  
TBS-T = TRIS-buffered saline including 0.02% Tween 20, HRP = horseradish peroxidase. 
To add a second set of primary antibodies (e.g. for housekeeping genes as a 
loading control) the membranes could be stripped with 50 mM sodium hydroxide 
(NaOH) for 10 minutes after washing with H2Odd. Blocking with powdered milk, 
Molecular target Description, species Dilution Brand 
Primary antibodies 
anti-IFIT1 
GTX103452; 
polyclonal, rabbit 
1:1000 in TBS-T with 
5% powdered milk 
GeneTex 
anti-Phospho-Stat1 
58D61; 
polyclonal, rabbit 
1:1000 in TBS-T with 
5% BSA 
Cell signaling 
Technologies 
anti-Stat 1 
sc-591; 
polyclonal, rabbit 
1:500 in TBS-T with 
5% powdered milk 
Santa Cruz 
Biotech 
β-Actin A4700; 
monoclonal, mouse 
1:5000, TBS-T with 
5% powdered milk 
Sigma Aldrich 
Secondary antibodies 
anti-Rabbit IgG HRP-coupled, goat 1: 8000 in TBS-T with 
5% powdered milk 
Bio-Rad 
anti-Mouse IgG HRP-coupled, goat 1: 8000 in TBS-T with 
5% powdered milk 
Bio-Rad 
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the addition of the antibodies and following steps were then executed as 
described above. 
2.6.2 “Real-time-quantitative Polymerase Chain Reaction (qPCR) 
RNA was isolated using the NucleoSpin® RNA kit (Macherey-Nagel, Düren, 
Germany) according to the manufacturer´s instructions. 500 ng of each RNA 
sample were mixed with 2 µl M-MLV RT buffer (Promega, Madison, WI, USA), 1 
µl RNase-inhibitor RNasin Plus (Promega), 1 µl oligo-dT-Primer (TIB MolBio, 
Berlin, Germany), 0.5 µl dNTP mix (Roti-Mix PCR3, Carl Roth) and added up to 
a total volume of 9.6 µl in RNAse-free water. Samples were then incubated at 
70°C for 2 min. After adding 0.4 µl reverse-transcriptase M-MLV RT H(-) Point 
Mutant (Promega), samples were incubated at 42 °C for 60 min.  
The cDNA samples were diluted (1/20) with tRNA-H2O; primers were used in a 
concentration of 500 nM. PCR was carried out in an iCycler (BioRad) with iQ5 
Multicolor Real-time Detection System (BioRad), using the following setup: 10 µl 
iQSYBR Green PCR Master Mix (Promega), 0.1 µl of each primer (100 µM stock), 
7.8 µl H20 and 2 µl cDNA (diluted 1/20). The following primer pairs were used: 
zfp64 (splicing variants 1,3,4) forward: ACCTGCCCACGGAAAGTAAT; zfp64 
(splicing variants 1,3,4) reverse: TATGGGGTTTGTCTCCCGTG; RPS18 
(housekeeping gene) forward: GAGGATGAGGTGGAACGTGT; RPS18 reverse: 
TCTTCAGTCGCTCCAGGTCT. PCR was carried out with the following thermal 
profile: 3 min at 95 °C with subsequently 40 cycles for 15 sec at 95 °C, 20 sec at 
60 °C, and 15 sec at 62 °C. Heating up for 1 min at 95 °C was followed by 1 min 
at 65 °C and 81 cycles at 65 °C cooling down to 20 °C. Target gene expression 
was evaluated via the 2-ΔCt method and normalized to the housekeeping gene 
RPS18 and subsequently graphed relative to the respective MOCK sample for 
each time point and expressed as "relative gene expression".” [103] 
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3 Results 
3.1 Preliminary experiments 
3.1.1 Cytotoxic effect of MeV-SCD monotherapy 
”Combinations of oncolytic viruses with various epigenetic compounds have been 
shown to result in the enhancement of their therapeutic efficacy, encouraging 
further investigation of novel combinatorial epi-virotherapeutic settings. In this 
context, we have tested the anti-tumoral potency of either resminostat, a novel 
oral histone deacetylase inhibitor (HDACi), or MeV-SCD, a prototypic suicide 
gene-armed measles vaccine virotherapeutic, in a commonly used panel of 
human hepatoma cell lines (HepG2, Hep3B, PLC/PRF/5).  
For this purpose, human hepatoma cells were infected in a first step with different 
multiplicities of infection (MOIs), ranging for HepG2 cells from MOI 0.01 to 1, for 
Hep3B cells from MOI 0.001 to 0.1, and for PLC/PRF/5 cells from MOI 0.001 to 
1 (Figure 3.1 (B)). Then, at 96 hours post infection (hpi), the remaining hepatoma 
cell masses were quantified by a sulforhodamine B (SRB) viability assay (Figure 
3.1 (A)). As a result, susceptibilities of these hepatoma cell lines to MeV-SCD 
mediated oncolysis were found to vary within a large range (Figure 3.1 (B)). Thus, 
in subsequent experiments we used different (adjusted) MOIs for hepatoma cell 
lines HepG2 (MOI 0.1), Hep3B (MOI 0.01), and PLC/PRF/5 (MOI 0.075). On this 
basis, remnant tumor cell masses of ≈75% (Figure 3.1 (B), dotted lines) were 
ensured for monotherapy with MeV-SCD. This ≈75% threshold was highly 
instrumental in providing still sufficient amounts of viable hepatoma cells to be 
killed in later tested scenarios, in which we applied the epi-virotherapeutic 
combination of MeV-SCD plus resminostat (MeV + Res).” [103] 
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(A)  
(B)  
Figure 3.1: Remaining tumor cell masses after single (monotherapeutic) treatment with MeV-SCD: 
(A): timeline for MeV-SCD single-agent treatment. (B, published in [103]) Human hepatoma cell lines 
HepG2, Hep3B, and PLC/PRF/5 were infected with the prototypic suicide gene-armed measles vaccine-
based virotherapeutic MeV-SCD at the indicated multiplicities of infection (MOIs). 96 hours post infection 
(hpi), the remaining hepatoma cell masses were determined by a sulforhodamine B (SRB) viability assay. 
Displayed are means and standard deviations (SD) of three independent experiments each carried out in 
quadruplicate. Dotted lines indicate the 75% threshold of remnant tumor cell masses at 96 hours post 
therapeutic intervention. MOCK: untreated control. 
3.1.2 Anti-tumor activities of resminostat on human hepatoma cell lines 
“In a second step, we also investigated the monotherapeutic cytotoxic potential 
of resminostat on human hepatoma cell lines. For this purpose, HepG2, Hep3B, 
and PLC/PRF/5 cells were incubated either for 24, 48, 72 or 96 hours (see 
timeline in Figure 3.2 (A)) with increasing concentrations of resminostat (ranging 
from 0.5 to 10 µM; see Figure 3.2 (B)). As a result, resminostat was found to 
reduce hepatoma cell masses being residual at 96 hours in a time- and dose-
dependent manner (see Figure 3.2 (B)) Again, we set out to attain a residual 
hepatoma cell mass of ≈75% also in the monotherapeutic use of resminostat” 
[103] (see Figure 3.2 (B), dotted lines), and agreed for subsequent combinational 
settings to focus on the time point 96 h post intervention, mainly owned to 
experiences in corresponding virus treatment. This could be easily achieved by 
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applying a uniform resminostat concentration of 1 µM for all three hepatoma cell 
lines used.” [103]  
 (A) 
  
(B) 
 
 
Figure 3.2 Cytotoxic effect of resminostat as a monotherapeutic agent in hepatoma cell lines  
Human hepatoma cell lines HepG2, Hep3B, and PLC/PRF/5 were treated with increasing concentrations of 
resminostat as indicated. Sulforhodamine B endpoint measurement was performed 24 h, 48 h, 72 h & 96 h 
later (see timeline in (A)). Values in (B) show means of at least three independent experiments performed 
in quadruplicates. Error bars: SD, Dotted lines indicate the 75% threshold of remnant tumor cell masses at 
indicated hours post resminostat treatment. Figures for 96 h values (columns on the far right) published in 
[103]. 
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3.2 Resminostat + MeV-SCD-based combination treatment 
settings 
3.2.1 Boosted cytotoxic/oncolytic effect of the epi-virotherapeutic 
combination treatment  
 
Figure 3.3: Application scheme for MeV-SCD and resminostat co-treatment in hepatoma cells 
“In a next step, we investigated the specific combinatorial epi-virotherapeutic 
potential of HDAC inhibition plus virus-mediated oncolysis (MeV + Res). For this 
purpose, hepatoma cells HepG2, Hep3B, and PLC/PRF/5 were first infected with 
MeV-SCD (using threshold-adjusted MOIs as described above). At 3 hpi, resmi-
nostat was added (see timeline in Figure 3.3) also in a threshold-adjusted manner 
(1 µM). As a result, boosted combined cytotoxic/oncolytic effects were observed 
in all three human hepatoma cell lines, HepG2, Hep3B & PLC/PRF/5, when 
compared with any of the two corresponding single agent / monotherapeutic 
treatment regimens, leading to a significant reduction of tumor cell masses as 
being quantified by SRB (Figure 3.4 (A), column on the left) and CellTiter-Blue 
(Figure 3.4 (B), column on the right) viability assays (purple bars (combi) versus 
blue/red bars (mono)). In detail, for HepG2 cells we found a reduction of 
hepatoma cell masses (i.e. SRB assay) for the combinatorial setting down to 
37.6% compared to 84.7% (resminostat alone) and 65.2% (MeV-SCD single 
agent treatment). In Hep3B cells, hepatoma cell masses were reduced to 59.1% 
(combi) whereas reduction to only 81.4% (resminostat) or 76.8% (MeV-SCD) 
could be achieved in monotherapeutic approaches. PLC/PRF/5 hepatoma cells 
reached a 48.1% residual tumor cell mass (combi) compared to 77.8% 
(resminostat) and 69.4% (MeV-SCD) in monotherapeutic approaches. 
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Interestingly, these findings could not be confirmed in primary human 
hepatocytes (PHH), where addition of resminostat to MeV infected primary cells 
did not further reduce PHH cell masses Figure 3.4, panel on the bottom).” [103] 
Comparison of cell viability, determined by the CellTiter-Blue assay (see Figure 
3.4 (B)), showed a decreased cancer cell viability for HepG2 cells in the 
combinational setting to 49.2% compared to resminostat (80.4%) and MeV-SCD 
(62.5%) single-agent treatment. In Hep3B cells, viability was found to be further 
reduced to a mean of 61.0%, compared to 78.1% (Res) and 74.4% (MeV-SCD) 
in the corresponding monotherapies. In this assay, viability of tumor cells was 
found for the cell line PLC/PRF/5 to be diminished to a minimum of 69.5% in the 
MeV + Res setting which is also a further reduction compared to 77.6% (Res) 
and 81.4% (MeV) respectively. In non-malignant PHH cells, no significant 
reduction was found in co-treated cells, compared to solely MeV-SCD infected 
samples. 
“Although addition of resminostat to MeV-infected cells did not further reduce 
PHH cell viability (Figure 3.4 (A) and (B) panels on the bottom) compared to the 
corresponding monotherapies, combination treatment (MeV + Res; (Figure 3.4 
(A), lower right panel, lane 4) did significantly affect PHH viability compared to 
the untreated control (Figure 3.4 (A) and (B), panel on the bottom, lane 1). This 
effect seems to be largely dependent on MeV-infection (Figure 3.4 (A) and (B), 
panel on the bottom, lane 3) as resminostat treatment alone had been found to 
have no impact on PHH viability (Figure 3.4 (A) and (B), panel on the bottom, 
lane 2). 
[…] Thus, a proof-of-principle has been provided for the profound anti-tumoral 
effects of a novel combination therapy based on the oral HDAC inhibitor 
resminostat (Res) combined with oncolytic measles vaccine virus MeV-SCD 
(MeV). Since this specific epi-virotherapeutic combination (Res + MeV) 
potentially could define a new therapeutic option for HCC patients, we further 
investigated molecular mechanisms possibly underlying the observed boosted 
anti-tumoral effect in detail.” [103] 
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Figure 3.4: Boosted cytotoxic effects obtained by epi-virotherapeutic co-treatment with MeV-SCD 
and resminostat  
Human hepatoma cell lines HepG2, Hep3B, and PLC/PRF/5 and non-malignant primary human hepatocytes 
(PHH; lower panel) were infected with MeV-SCD (at adjusted MOIs) and co-treated with resminostat (1 μM) 
at 3 hpi. Endpoint measurements were performed at 96 hpi using the SRB viability assay (left panel: (A), 
published in [103]) and CellTiter Blue Viability assay (right panel (B)). Displayed are means and standard 
deviations (SD) of at least three independent experiments for hepatoma cells and one experiment for PHH 
cells, each carried out in quadruplicates; p-values of one-way ANOVA with a Tukey post-test. Res: 
resminostat. MeV: suicide gene-armed measles vaccine-based virotherapeutic MeV-SCD. MOI: multiplicity 
of infection. hpi: hours post infection. 
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3.2.2 Other application settings in MeV-SCD/resminostat co-treatment 
3.2.2.1 Pre-treatment with resminostat 48 hours before infection 
To test whether chronology of resminostat co-application is of influence for 
treatment outcome (determined by residual tumor cell masses after epi-viro-
therapeutic intervention), we pre-treated the human hepatoma cell line panel with 
resminostat at varying concentrations for 48 hours (see timeline in Figure 3.5 (A)). 
Our idea was to induce a vulnerable state within the cells for subsequent boosted 
MeV-SCD infection by blocking residual innate immunity pathways. We found no 
significant benefit for the pre-treatment combinational setting (Figure 3.5 (B), 
purple bars) compared to the corresponding single-agent treatment regimens 
(Figure 3.5 (B), blue/red bars) and also compared to the application scheme 
described in section 3.2.1 (Figure 3.3).  
Figure 3.5: Combination setting of Res + MeV co-treatment (resminostat pre-treatment 48 hbi): 
(A) Application scheme for this setting: Human hepatoma cell lines were treated with resminostat as 
indicated and 48 h after pre-treatment, infection with prototypic measles vaccine vector MeV-SCD was 
performed. 3 hpi (MOI as indicated), a simple medium change was executed. (B) 96 hpi, residual cell masses 
were determined by SRB viability assay. Displayed are means of two independent experiments each carried 
out in quadruplicates + SD; hbi: hours before infection, hpi: hours post infection, MOI: multiplicity of infection. 
p-values of one-way ANOVA with a Tukey post-test. 
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Therefore, we ceased trying to continue further improvement of this specific 
chronological application setting, although to this point, optimized concentrations 
of resminostat as well as ideal MOIs for the combination setting (determined by 
the instrumentally installed ≈75% threshold for single-agent treatment) were yet 
to be found. 
3.2.2.2 Pre-treatment with resminostat 6 hours before infection and until 96 hpi 
In this prime-boost approach on epi-virotherapeutic treatment of primary liver 
cancer derived tumor cells, hepatoma cells were pre-treated with the HDAC 
inhibitor resminostat (1 μM) for 6 hours before infection took place. Resminostat 
was re-added (1 μM) again at 3 hours post infection (hpi) until endpoint 
measurement was performed 96 hpi (see timeline in Figure 3.6 (A)). We observed 
by tendency an enhanced cytotoxic/oncolytic effect in the combinational setting 
(Figure 3.6 (B), purple bars), which was found not to be statistically significant 
compared to both corresponding single-agent treatments (Figure 3.6 (B), blue/red 
bars). Although overall cumulative time of resminostat exposure was prolonged 
relative to section 3.2.1, no benefit compared to the treatment setting described 
above could be found, indicating that in general pre-treatment with resminostat in 
this specific cell line panel (in which none of the cell lines showed primary 
resistance phenomena towards MeV-SCD treatment) does not augment the 
benefits of the epi-virotherapeutic tumor therapy. 
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Figure 3.6: Prime-boost approach for epi-virotherapeutic treatment:  
(A) HepG2, Hep3B and PLC/PRF/5 cell lines were treated with resminostat (invariably 1 μM) 6 hours before 
infection (hbi) with armed measles virus MeV-SCD (at adjusted MOIs) and again 3 hpi as medium was 
changed. (B) Residual cell masses were determined 96 hpi using SRB endpoint measurement. Displayed 
are means of two independent experiments each carried out in quadruplicates + SD; p-values of one-way 
ANOVA with a Tukey post-test. 
3.2.3 Triple-therapy: Addition of prodrug 5-FC to the MeV/Res 
combination setting 
To exploit the full potential of our suicide gene-encoding oncolytic measles 
vaccine virus, MeV-SCD, we addressed the favorable opportunity to further 
reduce hepatoma cell masses by employing the expression of the Super-cytosine 
deaminase (SCD) in infected tumor cells. Therefore, as an amplification of the 
boosted cytotoxic/oncolytic effect observed in the resminostat/MeV-SCD 
combination setting in section 3.2.1, we extended the protocol by adding the 
prodrug 5-FC to MeV + resminostat co-treated cells 3 hours post infection (see 
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timeline in Figure 3.7 (A)). The successful conversion of 5-FC into the chemo-
therapeutic antimetabolite 5-fluorouracil (5-FU) has already been demonstrated 
by Lampe and colleagues [166] for HepG2 and Hep3B cells. The results of 
enhanced triple-therapy regimen are represented in Figure 3.7 (B): 
Figure 3.7: Triple-therapy: Addition of prodrug 5-FC to the MeV/Res combination setting:  
(A) Human hepatoma cell panel was infected with the oncolytic measles vaccine vector MeV-SCD (MOI as 
indicated) and co-treated with 1 μM resminostat and/or prodrug 5-FC at 0.01 mM 3 hours post-infection. (B) 
96 hpi sulforhodamine B viability assay was performed to measure remaining tumor cell masses. Displayed 
are means + SD of three independent experiments performed as quadruplicate. Res: resminostat. MeV: 
suicide gene-armed measles vaccine-based virotherapeutic MeV-SCD. MOI: multiplicity of infection. hpi: 
hours post infection; p-values of one-way ANOVA with a Tukey post-test. 
As expected, addition of the antifungal prodrug 5-fluorocytosine (uniformly 0.01 
mM) did not impair hepatoma cell growth (Figure 3.7 (B), green bars) in vitro and 
applied virus titer (at adjusted MOIs, Figure 3.7 (B), red bars) and concentration 
of resminostat (consequently 1 μM, Figure 3.7 (B), blue bars) were 
instrumentalized to achieve a residual cell mass of ≈ 75%. Addition of 5-FC to 
MeV-SCD-infected cells at 0.01 mM further reduced the percentage of viable 
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hepatoma cells (Figure 3.7 (B), green/red check pattern bars), indicating a 
successful conversion of 5-FC into cytotoxic 5-fluorouracil (5-FU). Importantly, 
the triple therapy setting, Res + MeV-SCD + 5-FC, (Figure 3.7 (B), yellow bars) 
was by tendency found to even further reduce remaining cell masses compared 
to either combination setting (MeV + Res [Figure 3.7, purple bars] as well as MeV 
+ 5-FC).  
3.3 Influences of resminostat on biological activity/growth 
characteristics of measles vaccine virus 
3.3.1 Examination of measles virus growth kinetics under the co-
treatment with resminostat 
After an enhanced cytotoxic/oncolytic effect was observed for the combination 
setting (see section 3.2.1), kinetics of virus infection and spread under the 
influence of resminostat were visualized by fluorescence monitoring utilizing the 
green-fluorescent protein (GFP)-encoding measles vaccine vector MeV-GFP. 
Therefore, the HepG2, Hep3B and PLC/PRF/5 cells were infected at an 
unvarying MOI of 0.1 with marker gene-encoding MeV-GFP or left untreated. 3 
hpi, resminostat was added or not. The resulting fluorescence pictures are 
displayed in Figure 3.8: in HepG2 (Figure 3.8, (A)) uninfected cells (MOCK), as 
expected, showed no fluorescence signal, and fluorescence microscopy of solely 
MeV-GFP-infected and resminostat co-treated cells showed no evidence of 
altered fluorescence signals, at later time points between the combinational 
setting and the MeV-mono-infection. Analogous observations could be made in 
Hep3B cells (Figure 3.8, (B)) and PLC/PRF/5 clones (Figure 3.8, (C)), but here 
typical MeV-mediated cytopathic/oncolytic effect due to syncytia-formation and 
subsequent lateral spread of infectious particles could be documented (e.g. at 72 
hpi for MeV-GFP and MeV-GFP + resminostat).  
Quantification of primary infection rates of MeV-GFP (see section 3.3.2) as well 
as replication and spread (see section 3.3.4) are demonstrated below. 
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(A) HepG2
 
(B) Hep3B 
 
Figure 3.8: Influence of resminostat co-treatment on MeV-GFP infection in hepatoma cells: 
HepG2, Hep3B and PLC/PRF/5 cells were mock infected (upper row), infected with MeV-GFP at MOI = 
0.1 (middle row) or co-treated with resminostat (lower row). Phase contrast and fluorescence pictures 
were taken at indicated time points. Infected cells show expression of green-fluorescent protein 
(GFP).The white scale bar on the lower right represents 1000 μm. Figure continued on next page. 
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Figure 3.8: Continued  
  
 
(C) PLC/PRF/5 
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3.3.2 “Resminostat-mediated enhancement of primary infection rates in 
hepatoma cell lines 
To further investigate the underlying molecular mechanisms of the epi-
virotherapeutic boosted anti-hepatoma effect, primary infection rates were 
determined using flow cytometry. For this purpose, HepG2, Hep3B, and 
PLC/PRF/5 cells were first infected with a derivative measles vaccine virus 
encoding the green-fluorescent marker protein (MeV-GFP) at a non-adjusted 
MOI of 1, and then co-treated with resminostat (1 µM). As a result, the percentage 
of infected hepatoma cells being determined at 24 hpi (a time point at which 
replication of MeV has not yet resulted in release of progeny virus particles and 
secondary infections of target cells) was found to be enhanced in all three human 
hepatoma cell lines in the combination groups (MeV + Res; Figure 3.9, purple 
bars) compared to the solely MeV-GFP infected groups (Figure 3.9, red bars). In 
detail, addition of resminostat elevated the percentage of MeV-GFP-infected 
HepG2 cells at 24 hpi from 13.2% to 21.9%, in Hep3B cells from 32.5% to 45.0%, 
both in a statistically significant manner; only in PLC/PRF/5 cells addition of 
resminostat was found to result in a minor rise of MeV-GFP-infected cells from 
9.2% to 11.1%, which was statistically insignificant.  
Interestingly, we found that all primary infection rates correlated quite well with 
the susceptibility of the hepatoma cell lines to MeV mediated oncolysis (Figure 
3.1). Notably Hep3B cells, exhibiting the most distinct MeV-mediated oncolytic 
effect already at quite low MOIs (i.e., MOI 0.01), showed the highest primary 
infection rate, indicating that the efficiency of hepatoma cell infection within the 
first 24 hours is crucial to oncolytic tumor cell destruction. In this context, it is of 
interest that resminostat was found to be able to induce a boost of primary 
infection, at least partially contributing to a boosted oncolytic effect being 
determined by the endpoint measurement of tumor cell viability (i.e. at 96 hpi).” 
[103] 
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Figure 3.9: Resminostat enhances rates of primary infection of human hepatoma cells by Measles 
vaccine virotherapeutics. 
Human hepatoma cell lines HepG2, Hep3B, and PLC/PRF/5 were infected with MeV-GFP at a standardized 
MOI of 1 and co-treated with resminostat (1 μM) from 3 hpi on. At 24 hpi, quantitative differences in primary 
infection rates (defined as the percentage of infected cells [%]) were determined by flow cytometry. 
Displayed are means and standard deviations (SD) of three independent experiments. p-values of one-way 
ANOVA with a Tukey post-test; MeV: virotherapeutic vector MeV-GFP encoding the GFP marker gene. MOI: 
multiplicity of infection. Res: resminostat. MOCK: untreated control. hpi: hours post infection. Figure 
published in [103]. 
3.3.3 Enhanced primary infection rates are independent of measles 
receptor (CD46) expression levels 
To analyze possible involvement of alterations in measles virus entry receptor 
(CD46) expression levels possibly underlying the observed enhanced primary 
infection rate of MeV-GFP in resminostat co-treated cells, mean fluorescence 
intensities as an index for CD46-receptor expression levels on human hepatoma 
cells were determined by flow cytometry (Figure 3.10). Untreated (MOCK-
infected) cells were used as a baseline expression level for CD46 and defined as 
100% (Figure 3.10, black bars). As a result, neither resminostat treatment (Figure 
3.10, blue bars), MeV-GFP infection (Figure 3.10, red bars), nor combinational 
treatment (Res + MeV, Figure 3.10, purple bars) was found to have a statistically 
significant effect on CD46-expression, although means of fluorescence intensity 
were generally found to be decreased in treated cells with no differentiation 
between virus infection and HDAC-inhibition (exception: in HepG2 cells, MeV-
GFP-treatment increased MFI in this specific case). Therefore, no correlation was 
found between an enhanced MeV-GFP primary infection rate under resminostat-
treatment and CD46-surface-receptor expression levels in our hepatoma panel 
and thus underlying mechanisms yet remain concealed.  
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Figure 3.10: Alterations of CD46 expression levels on MeV-GFP and/or resminostat-treated human 
hepatoma cells: 
Human hepatoma cells were infected with MeV-GFP at MOI 1 and treated with resminostat 1 μM. 24 hpi, 
phycoerythrin (PE) conjugated anti-CD46 antibodies or isotype control was used for staining of HepG2, 
Hep3B and PLC/PRF/5 cell lines and expression levels were determined by flow cytometry. Mean 
Fluorescence Intensity (MFI) was calculated as ratio of the arithmetic means of CD46-stained / isotype 
control-stained cells. Displayed are Means and SEM of three independent experiments. Statistical analysis 
carried out with a one-way ANOVA and a Tukey post-test; n.s.: not significant  
3.3.4 “Addition of resminostat does not impair MeV replication and 
spread  
To gain further insight into the kinetics of MeV-SCD replication and spread under 
the influence of resminostat, we worked out viral growth curves in 
absence/presence of resminostat (Figure 3.11). For this purpose, hepatoma cells 
were infected with MeV-SCD at adjusted MOIs as being defined before (HepG2: 
0.1; Hep3B: 0.01; PLC/PRF/5: 0.075). At 3 hpi, resminostat (1 µM) was added 
and MeV replication was quantified at 3, 24, 48, 72, and 96 hpi. As a result, we 
did not find any impairment of MeV-SCD replication and spread in HepG2 and 
PLC/PRF/5 hepatoma cell cultures (Figure 3.11, panels at the top and at the 
bottom). Interestingly, in Hep3B cells (Figure 3.11, panels in the middle) we found 
a slight, statistically insignificant enhancement of MeV progeny virus production 
in the presence of resminostat (both for cell associated as well as for MeV 
particles released into cell culture supernatants).  
Therefore, boosted anti-tumoral effects of the epi-virotherapeutic combination 
treatment (MeV + Res) seem to be largely independent of a putative resminostat-
enhanced viral replication and spread.” [103] 
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Figure 3.11: Resminostat does not impair replication of MeV-SCD and subsequent spread of progeny 
viral particles  
At 3, 24, 48, 72, and 96 hpi, cell lysates (comprising cell associated MeV particles; panels on the left) and 
supernatants (comprising MeV particles being released into cell culture medium; right column) were sampled 
either from solely MeV-SCD infected human hepatoma cells (HepG2, Hep3B, PLC/PRF/5; employing 
adjusted MOIs) or obtained after epi-virotherapeutic co-treatment with resminostat applied at a concentration 
of 1 µM (MeV + Res). Vero cells were used for virus titrations and results were converted into PFU/ml. 
Results of solely MeV-infected cells (red lines) are displayed along with results of MeV + Res co-treated 
cells (purple lines). Solid lines are representative for the quantification of cell-associated viral particles (left 
column), whereas dotted lines are used to highlight viral particles being released into hepatoma cell 
supernatants (column on the right). Means and standard errors of the mean (SEM) are shown for three 
independent experiments. PFU: plaque forming units. hpi: hours post infection.  
Figure modified from version published in [103]. 
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3.4 “Resminostat-induced downregulation of zfp64 in MeV 
infected hepatoma cells 
To provide proof for an unimpaired activity of resminostat in the course of MeV-
based infections of human hepatoma cells, we determined zinc finger protein 64 
(zfp64) expression levels, which functions as a well-established surrogate 
parameter for the pharmacological activity of resminostat, in absence/presence 
of MeV-SCD. As shown before [136], when resminostat (1 µM) was applied alone 
(i.e. in absence of MeV-SCD) it was found to inhibit zfp64 mRNA production quite 
effectively in all three human hepatoma cell lines at early time points, i.e. at 5 
hours after addition of resminostat (Figure 3.12, blue bars). Interestingly, when 
resminostat (1 µM) was added subsequent to infections with MeV-SCD 
(employing adjusted MOIs), lower zfp64 mRNA expression levels were observed 
when being compared to untreated controls (Figure 3.12, purple bars). In 
contrast, monotherapeutic applications of MeV-SCD (Figure 3.12, red bars) were 
found to enhance zfp64 expression levels in HepG2 cells and no alteration in 
zfp64 expression was found in PLC/PRF/5 cells. Thus, resminostat-induced 
downregulation of zfp64 expression was found to take place also in the course of 
MeV-based infections of human hepatoma cells, indicating an unimpaired effect 
of resminostat in this specific epi-virotherapeutic context.” [103] 
 
Figure 3.12: Expression levels of zfp64 (pharmacodynamic biomarker for resminostat activity) in 
human hepatoma cell lines after epi-virotherapeutic (Res + MeV) treatment:  
HepG2, Hep3B, and PLC/PRF/5 cells were infected with MeV-SCD at indicated MOIs and co-treatment with 
resminostat (1 µM) took place from 3 hpi on. RNA was isolated after 5 hours of incubation with resminostat. 
Then, zfp64 expression levels were determined using RT-qPCR. Values were normalized to the house-
keeping gene RPS18 (Ribosomal-protein S18) and relative expression is displayed compared to 
corresponding control samples (MOCK). Data of one experiment are shown. Figure published in [103]. 
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3.5 “Epi-virotherapeutic treatment (MeV + Res) enlarges 
apoptosis of hepatoma cells 
To gain additional insight into boosted anti-tumoral effects of this specific epi-
virotherapeutic (MeV + Res) treatment, we also analyzed cell cycle profiles of our 
human hepatoma cell panel. Again, HepG2, Hep3B, and PLC/PRF/5 cells were 
infected with MeV-SCD or mock infected and resminostat was added at 3 hpi or 
not. At 96 hpi, intracellular DNA was stained with propidium iodide and the 
percentage of hepatoma cells within each phase of the cell cycle was determined 
via flow cytometry (see Figure 3.13 (B)). Single-agent treatment with resminostat 
(Res; 1 µM) led to a slight enhancement of the sub2N fraction of hepatoma cells 
with hypoploid DNA content, indicating intracellular DNA fragmentation as a 
consequence of an ongoing apoptotic program (HepG2 (control / Res): 11.6% / 
20.8%; Hep3B: 13.6% / 25.2%; PLC/PRF/5: 6.1% / 11.9%). In contrast, infections 
with MeV-SCD (MeV) again being performed at adjusted MOIs (HepG2: 0.1; 
Hep3B: 0.01; PLC/PRF/5: 0.075) were found to augment the sub2N fraction 
(HepG2: 42.6%; Hep3B: 17.9%; PLC/PRF/5: 45.0%). Most interestingly, 
combinational epi-virotherapeutic treatment (MeV + Res) was found to further 
increase the rates of apoptotic cells (HepG2: 70.6%; Hep3B: 39.7%; PLC/PRF/5: 
62.7%). Thus, the epi-virotherapeutic combination therapy showed a substantial 
induction of apoptosis in all human hepatoma cell lines investigated, leaving only 
few tumor cells capable to proliferate.” [103] 
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(A) 
HepG2 
MOCK resminostat MeV MeV + Res 
 
(B) 
 
Figure 3.13: Cell cycle profiles of human hepatoma cells undergoing epi-virotherapeutic co-
treatment with MeV-SCD and resminostat: 
Human hepatoma cell lines HepG2, Hep3B, and PLC/PRF/5 were infected with MeV-SCD (MeV) or mock 
infected (MOCK) and resminostat (Res) was added at 3 hpi or not. Intracellular DNA was stained with 
propidium iodide (PI) at 96 hpi and measured by flow cytometry. (A) Exemplary raw data results for HepG2: 
area under the curve of different cell cycle phases are colorized (B) Combinatorial treatment (MeV + Res) 
was found to enhance the population of hypoploid/apoptotic cells (black vertical bars: sub2N) compared to 
corresponding single-agent treatments (MeV or Res) while concurrently diminishing fractions of proliferating 
cells (represented in cell cycle phases S and G2). Means of three independent experiments carried out in 
duplicates or triplicates are shown; p-values of one-way ANOVA with a Tukey post-test. (B) modified from 
version published in [103]. 
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3.6 “Resminostat impedes IFIT-1 expression after exogenous 
IFN-β stimulation 
To investigate putative immunomodulating effects of resminostat on the 
interferon (IFN) pathway being important for the innate immune defense against 
infections with virotherapeutics, modulations of IFIT-1 expression and Stat1 
phosphorylation were analyzed by immunoblotting. Notably, human hepatoma 
cell lines HepG2, Hep3B, and PLC/PRF/5 were found to be unable to produce 
detectable amounts of endogenous IFN-β neither at base-line (MOCK) nor after 
infection with MeV-SCD when using adjusted (low) MOIs (data not shown).” [103] 
Consequently, no detectable expression of IFN-stimulated genes, such as      
IFIT-1 was discovered in MeV-infected cells at low MOIs (data not shown). This 
can be considered as an indication for defects in innate immunity-dependent 
recognition of virus-associated pathogen-associated molecular patterns (PAMPs) 
in every single of our hepatoma cell lines. Thus, a possible explanation for our 
earlier observations in our preliminary experiments was found, where no 
resistance towards measles-based oncolysis was noted, neither in HepG2, 
Hep3B nor PLC/PRF/5 cell lines, implying severe acquired defects in defense 
reactions during malignant transformation towards intruding viruses for these 
particular cell lines. 
“Therefore, we had to pre-stimulate hepatoma cells with exogenous human     
IFN-β (1,000 U/ml) for 24 hours, which then led to a significant induction of IFIT-
1 expression and expression of Stat1 and its phosphorylation (P-Stat1) in all three 
hepatoma cell lines (Figure 3.14; lane 2 in all panels). In unstimulated/untreated 
controls, we found no baseline expression of IFIT-1 and no detectable amounts 
of P-Stat1 (Figure 3.14; lane 1 in all panels). As expected, treatment with 
resminostat (5 μM) alone did not induce IFIT-1 expression nor phosphorylation of 
Stat1 (Figure 3.14; lane 3 in all panels). However, when adding resminostat (5 
μM) coincident on IFN-β stimulated (1,000 U/ml) hepatoma cells , a profound 
suppression of IFIT-1 expression was observed in HepG2, Hep3B, and 
PLC/PRF/5 hepatoma cells, but no alteration in the phosphorylation status of 
Stat1 (Figure 3.14; lane 4 in all panels). Thus, all three human hepatoma cell lines 
were unable to induce a profound antiviral state, showing the potential of 
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resminostat as an immunomodulating compound to favor an enhanced virus 
mediated oncolysis in combination therapies with oncolytic measles vaccine 
viruses.” [103] 
 
Figure 3.14 IFN-β induced expression of IFIT-1 is suppressed by resminostat, whereas 
phosphorylation of Stat1 is not: 
HepG2, Hep3B, and PLC/PRF/5 cells were first stimulated with IFN-β for 24 hours or left unstimulated and 
then treated with resminostat (5 µM) or left untreated. IFIT-1 expression as well as phosphorylation and 
expression of Stat1 were analyzed by immunoblotting. β-Actin was used as a loading control. Shown are 
representative blots of three independent experiments. Figure published in [103] 
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4 Discussion 
“Despite recent improvements in the treatment of advanced stage hepatocellular 
carcinoma (HCC), clinical outcome for patients in late stages of this cancer entity 
is still poor and therefore further improvements of therapy modalities are urgently 
required.” [103] 
4.1 Boosted cytotoxic effects in the epi-virotherapeutic 
approach 
“Here, we investigated the potential benefit of a new epi-virotherapeutic 
approach, combining a novel histone-deacetylase inhibitor (resminostat [135]) 
with a state-of-the-art oncolytic measles vaccine virus (MeV-SCD [166]) in a 
panel of three human hepatoma cell lines. We found all hepatoma cell lines to be 
primarily susceptible to infection with MeV-SCD (defined by a remnant tumor cell 
mass of < 50% at 96 hpi at MOI 1 [90]), but susceptibility to virus infection was 
found to vary by a factor of 10 between the different hepatoma cell lines. 
Treatment with resminostat alone (monotherapeutic approach) resulted in a 
coincided dose-dependent reduction of tumor cell masses in all three hepatoma 
cell lines. However, coadministration of resminostat and MeV-SCD (Res + MeV) 
resulted in a potentiated oncolysis/cytotoxic effect warranting further 
investigations on this combinational therapy regimen. In contrast, in non-
malignant primary human hepatocytes (PHHs) no enhancement of cell mass 
reduction was found when comparing the epi-virotherapeutic approach (Res + 
MeV) to any of the monotherapeutic modalities, suggesting the combinational 
approach to be safe for hepatocytes and possibly also for other non-transformed 
cells. However, when comparing mock-treatment of PHH cells with the 
combinational (Res + MeV) treatment setting of PHH cells, a reduced PHH 
viability was found (Figure 3.4, lower panel). Of note, such MeV-SCD-triggered 
effects on in vitro cultured non-malignant primary human hepatocytes (PHHs) has 
already been found before (our unpublished data). Of note and in contrast to 
these in vitro findings, in vivo experiments in nude mice [166, 167], in transgenic 
mice as well as in macaques [168] were overall well tolerated without revealing 
any safety concerns (e.g., no rise in liver enzymes). Beyond that, results of 
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published clinical trials using measles vaccine viruses (e.g.[39-41]) exhibited 
excellent safety profiles not indicating induction of any organ problems such as 
liver failure.” [103] 
“We previously have demonstrated that resistance phenomena to MeV-SCD-
based oncolysis could be overcome by increasing the MOI of MeV-SCD or by 
employing the suicide gene function of MeV-encoded Super-cytosine deaminase 
(SCD), which results in converting the non-toxic antifungal prodrug 5-FC to the 
well-known cytotoxic drug 5-FU [79, 90, 166, 169].“ [103] Beyond that, we were 
able to show that exploitation of MeV-SCD-encoded prodrug conversion system 
(SCD) by addition of 5-FC to the Res + MeV co-treated cells - representing a 
triple therapy - was able to further enhance anti-tumor efficacy. These findings 
can be used to provide another therapeutic tool to further upgrade epi-virotherapy 
(which was accompanied by enhanced primary infection rates) as this triple-hit 
strategy can result in increased release of potentially antigenic tumor epitopes by 
tumor cell rupture. 
Nevertheless, as suicide gene function is dependent on preceding infection of 
tumor tissue, “increasing the dosage of administered viral vectors in patients is 
yet limited due to constraints in the respective manufacturing processes. And as 
those oncocytotoxic agents face various biological barriers (consisting e.g. of the 
host immune system as well as the tumor microenvironment), it is essential to 
enhance OV potency by prudent combination strategies.” [103] 
4.2 HDACi + OV treatment: is apoptosis the answer? 
“In our epi-virotherapeutic combination setting, enhanced hepatoma cell mass 
reduction was associated with a boosted rate of cells with hypoploid intracellular 
DNA content indicating an ongoing apoptotic program. Previous work by others 
has confirmed this mechanism of action when combining HDACi with OVs. The 
combination of e.g. either entinostat (MS-275) or vorinostat (SAHA) together with 
a VSV-based virotherapeutic vector was found to enhance intrinsic apoptotic 
pathways, a pattern which could also be observed in a combination study 
employing the HDACi valproic acid (VPA) together with the virotherapeutic 
parvovirus vector H-1PV [150]. In contrast, combination of trichostatin A and 
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HSV-1 mainly induced proliferation/cell cycle arrest by induction of p21 [170]. 
Other HDACi / OV combination studies found an enhanced therapeutic effect by 
induction of oxidative stress [150], whereas combination of vorinostat with VSV 
resulted in an induction of autophagy via modulation of NF-κB signaling [171]. 
Finally, addition of TSA to oncolytic treatment with HSV resulted in anti-
angiogenic effects indicated by a reduction in secretion of VEGF [149].” [103] 
Therefore, the precise mechanism of action for combining oncolytic viruses with 
inhibitors of histone deacetylases needs to be fully elucidated, as tumor cell killing 
by oncolytic viruses is not entirely describable by classical concepts of apoptosis 
[29]. This is owned to the experience that intruding virus pathogens often take 
over host cell transcription and translation equipment, thus limiting the initiation 
of classical pro-apoptotic pathways [172]. Yet combination studies on HDACi with 
several anti-cancer agents revealed a synergistic induction of apoptosis as the 
predominant mechanism of activity, as re-sensitization to apoptotic stimuli and 
concomitant activation of apoptotic pathways were identified in many cases [105]. 
4.3 Influences on virus biology by epigenetic manipulation 
4.3.1 MeV-SCD replication and spread is hardly affected by resminostat 
“Enhanced oncocytotoxic effects of epi-virotherapeutic treatment modalities have 
frequently been associated with a facilitation of virus replication and spread [146, 
150, 170], which seems to be dependent on dosing schedules. Thus, HSV 
replication could be enhanced by HDACi pretreatment but not by simultaneous 
co-treatment [147]. Nevertheless, no influence was found neither on primary 
infection rates nor on virus replication and spread in a setting of TSA plus HSV-
1 (G47∆) [149] in different human proliferating endothelial cells and cancer cell 
lines. When testing a larger panel of HDAC inhibitors, some, but not all HDACi 
were found to increase replication of a HSV-1 based virotherapeutic in breast 
cancer cells [148]. […] Here, we report that co-treatment with resminostat, a novel 
oral histone deacetylase inhibitor, did not negatively influence MeV-SCD 
replication and spread but was found to increase rates of primary infection of 
human hepatoma cells. Hereby, the moderate effects on enhanced virus entry 
did not translate into increased viral titers in the replication assays. Furthermore, 
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MeV RNA synthesis and assembly require a plethora of host factors, e.g. heat-
shock-protein 72 (HSP), casein kinase II, peroxiredoxin 1 (PRDX1), several 
unidentified kinases and structural cytoskeletal proteins such as actin [173]. 
These elements could all be possible intersections with the pleiotropic activities 
of HDACi compounds such as resminostat but have not been further elucidated 
so far. Accordingly, further work has to bring light into these interplays for the 
respective combination of MeV-SCD with resminostat in hepatoma cells and 
preferably also in other tumor cell entities. Additionally, we did not observe any 
enhanced or decreased oncolytic effect when varying the timing of resminostat 
application (adding resminostat before or after infections with MeV-SCD). 
Accordingly, we were able to reason that resminostat treatment hardly interacts 
with the process of measles vaccine virus replication, at least in cancer cells 
lacking a sufficient antiviral program. 
Variations in MeV-induced cell cytotoxicity among different cancer entities / cell 
lines seem to be dependent on a multitude of (independent) factors, including 
virus-specific as well as tumor cell-specific biologies, which have lately been 
characterized by Noll et al. [90] for our study virus MeV-SCD on the NCI-60 tumor 
cell panel. In this work, primary resistance phenomena were observed for about 
40% of the tested tumor cell lines; but not all resistant tumor cell lines were able 
to induce an antiviral state via the IFN-signaling pathway, clearly indicating the 
existence of further determinants being involved in the variation of tumor cell line-
specific MeV-mediated cytotoxicities. In this context, it is of interest that Lampe 
et al.[166] identified MeV-SCD-mediated oncolysis not to be solely dependent on 
functionally intact apoptotic pathways, a finding which underlines the diversity of 
the complex virus-tumor-cell-interactions leading to cancer-cell destruction. In 
another work, Berchtold et al.[79] found high expression levels of the measles 
entry receptor CD46 on tumor cell surfaces well correlating with high primary 
infection rates of our MeV virotherapeutics. However, this feature was not found 
to apply to our combinational therapy regimen (Res + MeV): hepatoma cell-
specific expression levels of CD46 were not found to be enhanced by resminostat 
co-treatment. Another point that one has to consider is the diverse genetic 
equipment distinguishing even our small panel of hepatoma cells (e.g. p53 
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expression is not altered in HepG2 cells; no expression of p53 can be detected 
for Hep3B cells, and PLC/PRF/5 cells exhibit reduced p53 levels [174]), leading 
to distinct rates of apoptosis or altered regulation of cellular protein biosynthesis 
following virus infection.” [103] 
Observations by Workenhe et al.[175] on two herpes-based vectors with different 
replication properties indicate that “initial stages of immunogenic virus replication 
are more important than persistence of a replicating virus within the tumor”[175], 
thus supporting our findings that an enhanced primary infection rate with marginal 
effects on subsequent replication and spread can favor an increased antitumor 
immunity. 
4.3.2 Resminostat does not alter measles entry receptor CD46 
expression levels 
“Additional combination approaches applying adenoviral virotherapeutics 
revealed further mechanistic insights into the complex interactions of OVs with 
HDACi, as adenovirus receptor CAR was found to be upregulated in presence of 
HDACi resulting in enhanced primary infection rates. Interestingly, ongoing 
HDAC inhibition then resulted in antagonistic interactions and was found to 
diminish adenovirus replication and spread [152, 176].” [103] In our own 
experiments, hepatoma cells showed rarely any alterations in CD46 MeV entry 
receptor expression levels, if at all, a slight downregulation following both 
monotherapies as well as in the combinational approach was noticed. This 
observation was described earlier (e.g. [177, 178]), as MeV-Edm strain vaccine 
viruses were found to be involved in post-infection down-regulation of CD46 but 
not SLAM/CD150 MeV receptor. “Recapitulating those findings, influences on OV 
replication and spread by coadministration of HDAC inhibitors seem to be 
multifactorial and no general rules can be applied, as outcomes seem to be 
greatly dependent on the specifics of the oncolytic vector system under 
evaluation and appertaining replication machineries as well as the particular 
HDAC inhibitor under investigation.” [103] 
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4.4 Resminostat functions as an immunomodulator in 
hepatoma cells 
4.4.1 Interference with the host cell interferon system 
“Among the multitude of genetic and epigenetic alterations which tumor cells 
acquire in the process of carcinogenesis, leading to independence of apoptotic 
signals, unrestricted proliferation and concealment of tumor cells from immune 
responses, some are responsible for a disruption of tumor pathways required for 
sufficient innate immunity signaling, making them preferred targets for oncolytic 
viruses. Accumulation of defects in interferons and interferon stimulated genes 
are vital for tumor evolution, as these pathways encompass involvement in 
programmed cell death [179], inhibition of angiogenesis [180] and 
immunostimulatory effects (e.g. tumor cell antigen expression) [181].  
In the context of human hepatoma cell infections we found that MeV, when used 
at low MOIs, was not able to induce any detectable amounts of IFN-β, an 
inflammatory cytokine with a central role in the cellular antiviral repertoire [182], 
indicating defects in pathogen recognition. A screening on the NCI-60 tumor cell 
panel revealed that about 75% of tumor cell lines were found to have defective 
IFN-responses [142, 183]. However, the same does not necessarily apply to 
primary tumor cells [142] and in-patient situations, in which primary resistance 
phenomena towards oncolytic virotherapy are observed.  
Measles vaccine virus strains (such as the Edmonston strain used in this work), 
but not wild-type measles virus, induce production of type I IFN in monocyte-
derived dendritic cells and peripheral blood lymphocytes [101, 102]. Therefore, it 
is likely that monocyte-derived dendritic cells being part of the tumor micro-
environment are responsible for a sturdy production of type I IFN, inducing (via 
paracrine secretion processes) an antiviral response in tumor cells lacking virus 
recognition. On the other hand, inhibition of different components of the IFN 
response has previously been shown to increase virus replication as well as virus 
yield in tumor cell cultures [184]. Therefore, combination strategies of OV and 
IFN-blocking agents potentially could help to overcome such limitations for the in-
patient situation. 
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To address this heterogeneity in tumor cell susceptibility towards oncolytic viro-
therapy, HDAC inhibitors can be employed to repress innate immunity signaling 
with restriction to malignant cells [93]. Interestingly, HDACi were found to have 
the potency to undermine antiviral immunity resulting in enhanced OV replication 
[142]. Mechanistically, inhibition of HDAC activity by TSA was found to inhibit 
IFN-β production and silencing of HDAC6 was correlated with an increased 
replication of VSV [185]. Beyond those findings, HDAC inhibition with TSA/VPA 
resulted in an impairment of ISG expression after exogenous stimulation with 
IFN-β without altering activation of Stat proteins and ISGF3 formation [186]. In 
detail, HDAC1 was found to associate with Stat1 and Stat2 and inhibition by 
HDACi leads to a diminished transcription in response to IFN-α [187]. To 
summarize those observations, treatment with HDAC inhibitors has been found 
to inhibit both IFN secretion and transcriptional activity of several interferon 
stimulated genes. In line with these discoveries, we here investigated the 
potential of resminostat as a potent inhibitor of class I & IIb HDAC (including 
HDAC1 and HDAC6) to inhibit induction of ISG. We showed that resminostat 
suppressed expression of IFIT-1 in HepG2, Hep3B, and PLC/PRF/5 cells after 
exogenous IFN-β stimulation, possibly preventing the induction of an antiviral 
state within hepatoma cells, thereby constituting a possible positive modulator for 
oncolytic virotherapy in tumor cells exhibiting a residually intact antiviral IFN 
response (a summary of possible resminostat interaction with innate immunity 
signaling is presented in Figure 4.1). Because of the deficient IFN-response found 
in our hepatoma panel, the enhanced cytotoxic effects of the epi-virotherapeutic 
combination approach can therefore not be attributed to the IFN-response 
(immuno-)modulating effects of resminostat. These are proposed additional 
benefits expected for the in vivo application of Res + MeV and have to be tested 
next in an immunocompetent animal model system. 
The IFIT family of antiviral proteins is found to be induced downstream of IFN-
stimulation following virus infection [100] with distinct activities against viral 
functions: e.g. general inhibition of translation initiation is achieved by interaction 
of IFIT proteins with eIF3 [98]. Furthermore, IFIT-1 (also known as ISG56) was 
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found to directly bind triphosphorylated RNA, which often occurs in the cytosol 
during life cycles of RNA viruses [188].” [103]  
 
Figure 4.1: Possible influences of resminostat on interferon (IFN) signaling: 
Virus derived pathogen-associated molecular patterns (PAMPs), such as ssRNA, dsRNA or 
triphosphorylated RNA are recognized e.g. by cytosolic receptors, such as RIG-I/MDA5 or TLRs, followed 
by signaling cascades resulting in NF-κB or IRF-3/IRF-7 activation and translocation to type I IFN promoter 
sites. Subsequently, newly synthesized inflammatory cytokines (such as type I IFN) bind to membranous 
IFN-receptors, leading to phosphorylation of Stat1 & Stat2, which form a heterotrimeric ISGF-3 complex 
together with IRF-9. ISGF-3 complex binding to the IFN-stimulated response element (ISRE) promoter sites 
triggers ISG (interferon-stimulated genes) production, such as IFIT (interferon-induced protein with 
tetratricopeptide repeats)-family proteins, which are responsible for induction of an antiviral state within the 
infected cell. HDACs are involved in IFN production and induction of ISGs. Resminostat is an inhibitor of 
HDAC1 & HDAC6 and is responsible for down-regulation of ZFP64, a positive regulator of NF-κB signaling. 
dsRNA: double stranded RNA; ssRNA: single-stranded RNA; RIG-I: retinoic acid-inducible gene 1; MDA5: 
melanoma-differentiation-associated protein 5; IPS-1: IFN-β promoter stimulator 1; TLR: Toll-like receptor; 
MyD88: myeloid differentiation primary response gene 88; HDAC: histone deacetylase; IRF: IFN regulatory 
factors; IFN: interferon; Stat: signal transducers and activators of transcription; ISGF: IFN-stimulated gene 
factor; ISRE: IFN-stimulated response element; ISG: IFN-stimulated gene; IFIT: IFN-induced proteins with 
tetratricopeptide repeats; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells.  
Figure published in [103] 
Additionally, type I Interferons were classified as so-called “danger-associated 
molecular patterns (DAMPs)” [21] that are induced by cellular distress, followed 
by activation of dendritic cells (DCs) with subsequent activation of antigen-
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specific T cells, which is defined as a so-called “immunogenic cell death” [21]. 
Resistance to adenovirus-based virotherapy was at least partly attributed to 
interferon-signaling by the tumor stroma/microenvironment (not the tumor cells 
themselves), resulting in recurrence of cancer disease in a complex mouse model 
[189]. Wojton et al.[190] suggested the usage of HDACi to dampen innate 
interferon signaling to circumvent resistance barriers mediated by the tumor 
microenvironment. 
Accordingly, transient inhibition of the type I interferon response by HDACi 
resminostat might favor MeV infection within the tumor niche and succeeding 
boosted immunogenic cell death. 
4.4.2 Additional immunomodulating functions by down-regulation of 
zfp64 
“NF-κB-signaling is also central for the activation of innate antiviral programs 
[191]. After cytosolic activation upon phosphorylation NF-κB induces 
inflammatory cytokines such as type I IFN [94]. Interestingly, zinc finger protein 
64 (zfp64) expression was found to be downregulated following resminostat 
treatment in vitro and in vivo [136]. We here found no negative impact upon zfp64 
mRNA levels when performing hepatoma cell infections with MeV-SCD, 
indicating that resminostat mediated effects are not impaired in the Res + MeV 
combination treatment setting. Of note, zfp64 has previously been found to be a 
positive modulator of NF-κB mediated signaling following TLR activated 
inflammatory response in macrophages and zfp64 knockdown was associated 
with the inhibition of TLR triggered production of IFN-β, TNF-α, and IL-6 [192]. 
Therefore, resminostat-mediated immunomodulation can be linked to these 
NF-κB dependent innate immunity signaling pathways throughout zfp64 down-
regulation as well (see also Figure 4.1).” [103] 
4.5 Future directions of immunovirotherapy 
Preclinical data rather overestimated the cytolytic effects of virotherapy in 
immunocompromised xenograft (mouse) models [21] and early successful case 
reports were attributed to induction of a general immunosuppression in those rare 
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case reports especially in patients with hematological malignancies that favored 
a systemic virus dissemination [193]. 
Direct oncolysis as well as virus replication and spread are often found to be 
limited by host innate (e.g. rapid neutralization by natural IgM and complement 
factors [58]) and adaptive immune response [194, 195]. Immune reaction in the 
context of oncolytic virotherapy, however, can be considered either friend or foe: 
induction of immunogenic cancer cell death (i.e. immunogenic apoptosis/ 
necrosis/pyroptosis and autophagy) by oncolytic viruses is associated with 
exposure of formerly dampened tumor associated antigens, damage associated 
molecular patterns (DAMPs) [196] and pathogen-associated molecular patterns 
(PAMPs) of virus origin. In turn, these immunogenic signals are recognized by 
antigen presenting cells (such as dendritic cells, DC) and are potent elicitors for 
an adaptive (T cell-mediated) antitumor immune response [197].  
As a consequence, the field of experts largely seems to agree that success of 
oncolytic virotherapy is dependent on both cytoreductive activity through direct 
tumor lysis and concomitant stimulation of a boosted adaptive immune response 
for long lasting disease control. To maximize this effect, viruses being in late-
stage clinical trials have shown to be of favorable efficiency when combining a 
direct oncolysis-dependent anti-tumor vaccinating effect with expression of 
immunostimulatory cargo, such as GM-CSF [21] (also tested for measles viruses 
by Grote et al.[198]). Finding a compromise balanced on a razor’s edge to 
maximize positive immune response effects, oncolytic viruses can be combined 
with other treatment modalities, such as radiation or classical chemotherapy.  
For example, in preclinical studies MeV-NIS has been successfully combined with 
immunosuppressive alkylans such as cyclophosphamide [199] and pretreatment 
with cyclophosphamide - being instrumental to delay a sufficient anti-viral 
response - was found to enhance virus replication at early time points of the 
treatment but did not delay MeV-NIS clearance at later time points. Based on 
these findings, a phase I/II clinical trial on patients with refractory multiple 
myeloma was launched (NCT00450814) and a following Phase II efficacy study 
as well (NCT02192775). Here, a transient immunosuppression leads to a 
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beneficial outcome without augmentation of treatment-associated toxicities, 
showing the general applicability of these approaches. Evidence gained to date 
leads to the conclusion that the immune modulation by HDACi is restricted to 
transformed cells without increased susceptibility of healthy tissue to viral 
infection [142]. Of course, these safety issues have to be addressed when 
designing a first epi-virotherapeutic clinical trial by systematic repetitive sampling 
and biopsy analyses.  
Another promising immunovirotherapeutic approach was identified, as innovative 
combination with systemic immunotherapies (e.g. immune checkpoint inhibitors 
like CTLA-4 and PD-1 antibodies) seems to be able to result in the induction of 
favorable inflammatory immune infiltrations even to metastatic tumor sites [200]. 
Releasing the brake of the antitumor T-cell response by checkpoint blockade was 
recently demonstrated by Engeland et al.[201], as the group generated measles 
vaccine vectors encoding for CTLA-4 and PD-L1 antibodies. Testing these 
vectors in a fully immunocompetent mouse model revealed (i) enhanced 
therapeutic efficiency of the combined treatment of measles infection and local 
expression of therapeutic antibodies as well as (ii) favorable immunological 
profiles, as total amounts of T cells were increased while regulatory T cells were 
found to be reduced within the tumors. These results encourage the further usage 
of this immunovirotherapeutic approach and underline the importance of a 
balanced interplay between direct oncolysis on the one hand and beneficial 
immunomanipulation on the other hand. 
“The intention of combining an oncolytic virus with an HDAC inhibitor is to 
generate a balanced treatment modality between temporary immunomodulation, 
favoring OV replication in cancer cells, and a maximum boosted host anti-tumor 
adaptive immune response through release of specific tumor antigens following 
measles infection.” [103]  
As HDAC inhibitors deregulate the epigenetic code of tumor cells on various 
levels, a multitude of possible effects on viral oncolysis can be assumed. 
Additionally, HDACi and OV combinations were found to synergistically inhibit 
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tumor blood flow by repression of pro-angiogenic mediators leading to so-called 
vascular shutdown and regression of tumor sites [143, 149].  
4.6 Perspectives 
The aim of this thesis was to establish a preclinical therapy regimen for the epi-
virotherapeutic treatment of hepatocellular carcinoma (HCC) using the oncolytic 
measles vaccine vector MeV-SCD and the epigenetically active compound 
resminostat.  
“When testing a panel of human hepatoma cell lines, we found (i) a significantly 
improved rate of primary infections when using oncolytic MeV under concurrent 
treatment with resminostat, (ii) a boosted cytotoxic effect of the epi-viro-
therapeutic combination (Res + MeV) with enhanced induction of apoptosis, and, 
quite importantly, (iii) an absence of any resminostat-induced impairment of MeV 
replication and spread. Beyond that, we were also able to show (iv) that 
resminostat, after hepatoma cell stimulation with exogenous human interferon-β, 
is able to prevent the induction of interferon-stimulated genes, such as IFIT-1. 
This finding outlines the possible impact of resminostat on cellular innate 
immunity, being instrumental in overcoming resistances to MeV-mediated viral 
oncolysis” [103] and therefore provides a strong rationale to establish this epi-
virotherapeutic approach as a multi-faceted treatment modality against cancer.  
“Our data lead to the conclusion that combination therapies of the novel oral 
HDAC inhibitor resminostat with the oncolytic measles vaccine virus MeV-SCD 
bear a great potential for patients with advanced hepatocellular carcinomas, 
especially as both agents are currently under clinical investigation, which could 
allow a fast translation of our results “from bench to bedside”. The full benefit of 
the combination therapy of both compounds for those HCC patients may be even 
considerably larger, as resminostat per se could function as an immuno-
modulating compound. This could potentially suppress cellular innate antiviral 
responses in hepatoma cells being refractory to virotherapy, leading to higher 
concentrations of viral vectors at the respective tumor sites.“ [103] 
These effects could potentially be accompanied by resminostat immune priming 
attributes, consisting of accelerated NK cell recruitment, enhanced TAA 
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expression and presentation by cancer cells, as well as releasing the brakes on 
T-cell-mediated anti-tumor immune response [137]. 
“Based on these promising results, the next logical step is to test this approach 
in an immunocompetent murine model and to design a first epi-virotherapeutic 
clinical trial employing resminostat together with MeV-SCD in patients exhibiting 
advanced stages of HCC.” [103]  
The design of a future clinical trial should thereby be based on systematic pre-
clinical evaluation of varied dosing intervals in a multiple-hit (virotherapy-)setting 
compared to a single-shot MeV administration and -varying overlapping dosing 
intervals of resminostat co-treatment. This could reveal an even more potent 
application scheme in this epi-virotherapeutic context, especially when carried 
out in an immunocompetent model system to reveal immunological interactions 
and therefore unveil the proposed full therapeutic benefit of the combination of 
MeV and resminostat. 
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5 Summary 
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related 
deaths worldwide and therapy options for advanced stages of disease are, 
despite recent advantages, considered relatively poor. 
Oncolytic viruses represent a novel therapy option for cancer treatment, as they 
were found to infect malignant tissue with subsequent substantial anti-tumor 
activity while toxicities for patients were generally found to be modest. 
Nevertheless, clinical testing of measles vaccine virus (MeV) as oncolytic vector 
platform revealed several limitations, such as inherent resistance phenomena as 
well as a lack of therapeutic efficiency. Therefore, prudent combination strategies 
are required to address those issues. 
Inhibitors of human histone deacetylases (HDACi) are investigated as a 
therapeutic option for various cancer entities with capability to induce cancer cell 
death as well as inhibition of tumor proliferation with concomitant additive 
immunomodulating potency. Interestingly, HDACi were found to dampen innate 
immunity signaling after infection with oncolytic vectors in tumor cells and are 
therefore considered as commendable combination partners for oncolytic 
virotherapy. 
Aim of this thesis was to investigate the potential of the epi-virotherapeutic 
combination using the prototypic suicide gene-armed measles vaccine-based 
virotherapeutic MeV-SCD and the oral HDACi resminostat for in vitro studies on 
a panel of three well-established hepatoma cell lines. To identify underlying 
mechanisms, alterations in virus biology parameters, as well as influences on 
tumor cell immune signaling and cell death were investigated.  
We found an enhanced cytotoxic/oncolytic effect for the epi-virotherapeutic co-
treatment (Res + MeV) compared to any of the two monotherapeutic modalities 
in human hepatoma cells, but not in non-malignant primary human hepatocytes 
(PHH), accompanied by an accumulation of tumor cells undergoing apoptosis. 
Rates of primary infection of hepatoma cells by MeV could be enhanced in the 
presence of resminostat, while no inhibitory effects of resminostat on subsequent 
MeV replication and spread were observed. On a molecular level, resminostat 
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was found to be a potent inhibitor of IFN-β-induced upregulation of IFIT-1 
(interferon-induced protein with tetratricopeptide repeats), distinguishing itself as 
a transient immunomodulator being instrumental in promoting oncolytic 
virotherapy.  
As both MeV and resminostat are currently under evaluation in several clinical 
trials, this epi-virotherapeutic combination therapy could be translated rapidly into 
clinical practice as an effective strategy against advanced stage liver carcinoma. 
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6 Zusammenfassung 
Das Hepatozelluläre Karzinom (HCC) gehört zu einer der häufigsten 
Krebstodesursachen weltweit und Behandlungsmöglichkeiten für 
fortgeschrittene HCC-Tumorstadien sind, trotz gewisser Fortschritte in den 
letzten Jahren, immer noch eingeschränkt. 
Der Einsatz onkolytischer Viren in der Krebstherapie stellt eine neuartige 
Behandlungsmöglichkeit in der Onkologie dar, da diese Viren malignes Gewebe 
infizieren, in diesem selektiv replizieren, dieses dabei lysieren und 
dementsprechend antitumorale Eigenschaften besitzen, wobei sich gleichzeitig 
die Nebenwirkungen für die Patienten bisher als ausgesprochen überschaubar 
erwiesen. Dennoch hat sich in der klinischen Überprüfung dieser Eigenschaften 
gezeigt, dass es für den Einsatz von Masern-Impfviren (MeV) als onkolytische 
Vektoren einige Beschränkungen gibt, die von primären Resistenzphänomenen 
bis zu einem Mangel an therapeutischem Effekt reichen. Daher sind wohlüber-
legte Kombinationsstrategien erforderlich, die diese Problembereiche elegant 
lösen können. 
Inhibitoren der Enzymgruppe der humanen Histon-Deacetylasen (HDACi) 
werden als Therapieoption für verschiedene Tumorentitäten in Betracht gezogen, 
da diese gezeigt haben, Krebszellen selbst zerstören zu können, diese an der 
Proliferation zu hindern und darüber hinaus zusätzliche immunmodulierende 
Eigenschaften besitzen. HDACi können dabei interessanterweise das 
angeborene zelluläre Immunsystem der Tumorzellen nach der Infektion mit 
onkolytischen Vektoren unterdrücken, sodass Histon-Deacetylase-Inhibitoren für 
die Kombination mit onkolytischen Viren hervorragend geeignet erscheinen. 
Ziel dieser Arbeit war, das Potenzial des epi-virotherapeutischen Kombinations-
ansatzes des neuen HDAC-Inhibitor Resminostat (Res) zusammen mit dem 
onkolytischen Masernimpfvirus MeV-SCD (das für ein sog. Suizidgen kodiert) an 
einer Auswahl von drei humanen Hepatomzelllinien zu charakterisieren. Um 
zugrunde liegende Mechanismen aufzudecken, wurden Untersuchungen auf 
Ebene der Virusbiologie (wie primäre Infektionsraten oder auch Replikations-
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kompetenz) durchgeführt. Darüber hinaus wurden Einflüsse der Kombinations-
therapie auf Signalwege des angeborenen Immunsystems der Tumorzellen, aber 
auch Mechanismen des programmierten Zelltodes beobachtet.  
Es konnte gezeigt werden, dass die epi-virotherapeutische Kombinations-
behandlung (Res + MeV) einen verstärkten zytotoxischen/onkolytischen Effekt in 
den humanen Hepatomzelllinien erzielt, dies jeweils im Vergleich zu den 
entsprechenden Monotherapien, jedoch nicht in untransformierten, gesunden 
primären Hepatozyten (PHH). Dieser Effekt konnte zumindest partiell auf eine 
vermehrte Anzahl an apoptotischen Tumorzellen zurückgeführt werden. Primäre 
Infektionsraten der Hepatomzellen mit MeV konnten durch Zugabe von 
Resminostat gesteigert werden, ohne dabei die nachfolgende Virusreplikation 
und -ausbreitung negativ zu beeinflussen. 
Auf molekularer Ebene zeigte sich Resminostat als potenter Inhibitor einer durch 
Stimulation mit humanem IFN-β (Interferon beta) induzierten Hochregulation von 
IFIT-1 (interferon-induced protein with tetratricopeptide repeats). Durch diese 
Resminostat-vermittelte transiente Immunmodulation kann wiederum eine 
erfolgreiche onkolytische Virotherapie potenziell gefördert werden. 
Da sowohl Masern-Impfviren als auch Resminostat derzeit in zahlreichen 
klinischen Studien getestet werden, könnte dieser epi-virotherapeutische 
Kombinationsansatz als effektive Behandlungsmöglichkeit des fortgeschrittenen 
Leberkarzinoms zügig im klinischen Alltag zur Anwendung kommen. 
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for epi-virotherapeutic treatment of hepatocellular carcinoma. Molecular 
Therapy — Oncolytics 2: 150019. 
Frau Dr. Berchtold war an der Konzeption der Studie beteiligt, hat die Arbeit 
betreut und das Manuskript korrigiert. Frau Dr. Berchtold hat die RNA-Isolation 
durchgeführt, deren Ergebnisse in Abbildung 5 des Manuskriptes dargestellt sind, 
war an den Western-Blot-Versuchen beteiligt, die in Abbildung 7 gezeigt sind, 
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(Fig. 2, Abbildung rechts unten) bei.  
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der RT-qPCR-Versuche, haben gemeinsam mit Frau Dr. S. Berchtold die 
zugehörigen Daten zur Verfügung gestellt, die in Abbildung 5 gezeigt werden. 
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Sämtliche Versuche - mit unten stehenden Ausnahmen - wurden (nach Ein-
arbeitung durch Frau I. Smirnow, MTA) von mir eigenständig durchgeführt.  
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Berchtold in Kooperation mit Frau Dr. T. Prenzel und Herrn Dr. S.W. Henning 
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entsprechender Beratung durch das Institut für Biometrie). 
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